

**PRODUCT MONOGRAPH**  
**INCLUDING PATIENT MEDICATION INFORMATION**

**PrEPCLUSA®**

**(sofosbuvir/velpatasvir) tablets**

**400 mg/100 mg**

**Antiviral Agent**

Gilead Sciences, Inc.  
Foster City, CA 94404  
USA

Date of Preparation:  
November 5, 2020

Gilead Sciences Canada, Inc.  
Mississauga, ON L5N 2W3  
Canada

[www.gilead.ca](http://www.gilead.ca)

Submission Control No.: 233923

## **TABLE OF CONTENTS**

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS .....	8
DRUG INTERACTIONS .....	15
DOSAGE AND ADMINISTRATION .....	26
OVERDOSAGE .....	28
ACTION AND CLINICAL PHARMACOLOGY .....	29
STORAGE AND STABILITY .....	34
SPECIAL HANDLING INSTRUCTIONS .....	34
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	34
<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>35</b>
PHARMACEUTICAL INFORMATION .....	35
CLINICAL TRIALS .....	36
MICROBIOLOGY .....	54
TOXICOLOGY .....	59
REFERENCES .....	61
<b>PART III: PATIENT MEDICATION INFORMATION .....</b>	<b>62</b>

**EPCLUSA<sup>®</sup>**  
sofosbuvir/velpatasvir

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form/Strength</b>	<b>Clinically Relevant Non-medicinal Ingredients</b>
oral	tablet 400 mg sofosbuvir/100 mg velpatasvir	Not applicable

*For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section.*

---

**INDICATIONS AND CLINICAL USE**

EPCLUSA (sofosbuvir/velpatasvir) is indicated for the treatment of chronic hepatitis C virus (HCV) infection:

- in adults and pediatric patients  $\geq 12$  years of age and weighing  $\geq 30$  kg without cirrhosis or with compensated cirrhosis
- in combination with ribavirin in adults with decompensated cirrhosis.

**Geriatrics ( $\geq 65$  years of age)**

The response rates observed for patients 65 years of age and over were similar to those of younger patients across treatment groups. EPCLUSA can be administered in geriatric patients (see **ACTION AND CLINICAL PHARMACOLOGY** and **CLINICAL TRIALS**).

**Pediatrics (< 18 years of age)**

The safety and efficacy of EPCLUSA in pediatric patients  $\geq 12$  years of age receiving EPCLUSA once daily have been established (see **ADVERSE REACTIONS** and **CLINICAL TRIALS**). Exposures to EPCLUSA in pediatric patients  $\geq 12$  to <18 years of age and weighing  $\geq 30$  kg were similar to those observed in adults.

The safety and efficacy of EPCLUSA in pediatric patients < 12 years of age or weighing < 30 kg have not been established.

**Patients Co-infected with Human Immunodeficiency Virus (HIV-1)**

Safety and efficacy have been established in HCV-infected adult patients, with or without cirrhosis, who are co-infected with HIV-1 (see **DOSAGE AND ADMINISTRATION** and **CLINICAL TRIALS**).

Safety and efficacy have not been studied in pediatric patients co-infected with HIV-1. The treatment of pediatric patients  $\geq 12$  years of age and weighing  $\geq 30$  kg and co-infected with HIV-1 is based on extrapolation of relevant clinical data (see **ACTION AND CLINICAL PHARMACOLOGY** and **CLINICAL TRIALS**).

## CONTRAINDICATIONS

EPCLUSA is contraindicated in patients with known hypersensitivity to any of the components of the product. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the Product Monograph.

When EPCLUSA is used in combination with ribavirin, the contraindications to ribavirin are also applicable to the combination regimen. Refer to the Product Monograph containing information on ribavirin for a list of contraindications for ribavirin.

## WARNINGS AND PRECAUTIONS

### Serious Warnings and Precautions

#### Potential for Hepatitis B Virus (HBV) Reactivation

Screen all patients for evidence of current or prior HBV infection before initiating EPCLUSA treatment. Cases of HBV reactivation, including those resulting in fulminant hepatitis, hepatic failure, and death, have been reported during HCV treatment and/or post-treatment with regimens containing direct acting antivirals (DAAs) in patients co-infected with HBV (see **WARNINGS AND PRECAUTIONS, Potential for Hepatitis B Virus Reactivation**).

### General

Treatment with EPCLUSA should be initiated and monitored by a physician experienced in the management of chronic hepatitis C virus (HCV) infection.

EPCLUSA should not be administered concurrently with other medicinal products containing sofosbuvir.

### Use with P-gp Inducers and/or Moderate to Strong Inducers of CYP

Medicinal products that are P-glycoprotein (P-gp) inducers and/or moderate to strong inducers of CYP2B6, CYP2C8, or CYP3A4 [eg, rifampin, St. John's wort (*Hypericum perforatum*) and carbamazepine] may significantly decrease plasma concentrations of sofosbuvir and/or velpatasvir leading to reduced therapeutic effect of EPCLUSA and potential loss of virologic response. These agents should not be used with EPCLUSA (see **DRUG INTERACTIONS**).

### Cardiovascular

### **Serious Symptomatic Bradycardia When Coadministered with Amiodarone**

Postmarketing cases of symptomatic bradycardia and cases requiring pacemaker intervention have been reported when amiodarone is coadministered with sofosbuvir in combination with daclatasvir or simeprevir. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir-containing regimen (HARVONI® [ledipasvir/sofosbuvir]). Bradycardia has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating HCV treatment. Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. Bradycardia generally resolved after discontinuation of HCV treatment. The mechanism for this effect is unknown.

Coadministration of amiodarone with EPCLUSA is not recommended. For patients taking amiodarone who have no other alternative, viable treatment options and who will be coadministered EPCLUSA:

- Counsel patients about the risk of symptomatic bradycardia.
- Cardiac monitoring in an in-patient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.

Patients who are taking EPCLUSA who need to start amiodarone therapy due to no other alternative, viable treatment options should undergo similar cardiac monitoring as outlined above.

Due to amiodarone's long half-life, patients discontinuing amiodarone just prior to starting EPCLUSA should also undergo similar cardiac monitoring as outlined above.

Patients who develop signs or symptoms of bradycardia should seek medical evaluation immediately. Symptoms may include near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion, or memory problems (see **ADVERSE REACTIONS, Post-Market Adverse Drug Reactions** and **DRUG INTERACTIONS**).

### **Potential for Hepatitis B Virus Reactivation**

Cases of HBV reactivation, including those resulting in fulminant hepatitis, hepatic failure, and death have been reported in HCV/HBV co-infected patients who were undergoing, or completed treatment with DAAs including EPCLUSA. To decrease the risk of HBV reactivation in patients co-infected with HBV, HBV screening should be performed in all patients prior to initiation of EPCLUSA for HCV treatment. Patients with positive HBV serology (HBsAg positive) and patients with serologic evidence of resolved HBV infection (ie, HBsAg negative and anti-HBc positive) should be monitored and treated according to current clinical practice guidelines to manage potential HBV reactivation (see **WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests**).

### **Hepatic Impairment**

The safety and efficacy of EPCLUSA have not been established in adult patients with severe hepatic impairment (Child-Pugh C) (see **DOSAGE AND ADMINISTRATION** and **ACTION AND CLINICAL PHARMACOLOGY**).

EPCLUSA has not been studied in pediatric patients with moderate or severe hepatic impairment.

Monitoring of liver function including direct bilirubin is recommended in patients with decompensated cirrhosis.

### **Resistance**

The efficacy of EPCLUSA has not been established in patients who have previously failed treatment with other regimens that include a NS5A inhibitor (see **MICROBIOLOGY, Cross Resistance**).

### **Sexual Function/Reproduction**

There are no data on the effect of sofosbuvir and velpatasvir on human fertility. No effects on fertility were observed in animal studies for sofosbuvir and velpatasvir (see **TOXICOLOGY**).

### **Patients with Other HCV Genotypes**

Data to support the treatment of patients with decompensated cirrhosis who are infected with HCV genotype 2 or genotype 4 are limited, and there are no data for genotype 5 and genotype 6 HCV-infected patients with decompensated cirrhosis. The indication for treatment of these patients is based on extrapolation of relevant clinical and *in vitro* data (see **CLINICAL TRIALS** and **MICROBIOLOGY**).

### **Special Populations**

#### **Pregnant Women**

##### ***Use without Ribavirin***

Pregnancy should be avoided while taking EPCLUSA as there are no data on the use of EPCLUSA in pregnant women. EPCLUSA should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Patients should be advised to notify their healthcare provider immediately in the event of a pregnancy.

No effects on pre- or post-natal development were observed in animal reproduction studies at the highest doses of sofosbuvir tested. In the rat and rabbit embryo fetal studies, and the rat pre/post-natal study, exposure to the predominant circulating metabolite GS-331007 at the highest dose was approximately 5-fold, 14-fold, and 6-fold the exposure in humans at the recommended clinical dose, respectively.

No effects on pre- or post-natal development have been observed in animal reproduction studies at the highest doses of velpatasvir tested. In the mouse, rat, and rabbit embryo fetal studies, and rat pre/post-natal study, velpatasvir exposure was approximately 31-fold, 6-fold, 0.7-fold, and 5-fold the exposure in humans at the recommended clinical dose, respectively.

### ***Use with Ribavirin***

If EPCLUSA is administered with ribavirin, the warnings and precautions for ribavirin, in particular the pregnancy avoidance warning, apply to this combination regimen. Women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for 6 months after the treatment has concluded. Routine monthly pregnancy tests must be performed during this time. Refer to the ribavirin Product Monograph for a full list of warnings and precautions for ribavirin.

### **Nursing Women**

It is not known whether sofosbuvir, velpatasvir, or their metabolites are excreted in human breast milk. The sofosbuvir predominant circulating metabolite GS-331007, and velpatasvir, are present in the milk of lactating rats; they had no clear effect on nursing pups. Because a risk to the newborn/infant cannot be excluded, mothers should be instructed not to breastfeed if they are taking EPCLUSA.

### **Pediatrics (< 18 years of age)**

The safety, pharmacokinetics, and efficacy of EPCLUSA in pediatric patients  $\geq 12$  years of age have been established in an open-label trial (Study GS-US-342-1143, Cohort 1) and are comparable to that observed in adults (see **ADVERSE REACTIONS, ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, and CLINICAL TRIALS**). Population pharmacokinetics-based simulations indicated exposures of sofosbuvir, GS-331007, and velpatasvir in pediatric patients  $\geq 30$  kg receiving oral once daily dose of sofosbuvir/velpatasvir 400/100 mg were similar to those observed in adults.

Pediatric patients with renal impairment have not been studied.

The safety and efficacy of EPCLUSA in pediatric patients < 12 years of age or weighing < 30 kg have not been established.

### **Geriatrics ( $\geq 65$ years of age)**

The response rates observed for patients 65 years of age and over were similar to those of patients < 65 years of age across treatment groups.

### **Liver Transplant Patients**

The safety and efficacy of EPCLUSA have not been established in patients with recurrent HCV infection after liver transplant.

### **HCV/HIV-1 Co-infection**

The safety and efficacy of EPCLUSA in HCV/HIV-1 co-infected adult patients have been established (see **CLINICAL TRIALS, Clinical Trial in Patients with HCV/HIV-1 Co-infection (ASTRAL-5)**). Efavirenz has been shown to significantly decrease the concentration of velpatasvir. Therefore co-administration of EPCLUSA with an efavirenz-containing HIV regimen in adults is not recommended (see **DRUG INTERACTIONS**).

EPCLUSA use in pediatric patients co-infected with HIV-1 has not been studied.

### **HCV/HBV Co-infection**

The safety and efficacy of EPCLUSA have not been established in HCV patients co-infected with HBV. HBV reactivation has been reported during treatment and post-treatment with DAAs in patients co-infected with HBV who were not undergoing treatment for HBV infection (see **WARNINGS AND PRECAUTIONS, Potential for HBV Reactivation**).

### **Monitoring and Laboratory Tests**

If EPCLUSA is administered with amiodarone, close monitoring for bradycardia is recommended. Refer to the amiodarone Product Monograph (see **WARNINGS AND PRECAUTIONS, Drug Interactions**).

Monitoring of liver function including direct bilirubin is recommended in patients with decompensated cirrhosis (see **ADVERSE REACTIONS**).

Clearance of HCV may lead to increased replication of HBV in patients who are co-infected with HCV and HBV; co-infected patients should be monitored for clinical and laboratory signs (eg, HBsAg, anti-HBc, HBV DNA, serum aminotransferase levels, bilirubin) for hepatitis flare or HBV reactivation during and at post-treatment follow-up as clinically appropriate (see **WARNINGS AND PRECAUTIONS, Potential for HBV Reactivation**).

As liver function may improve during treatment with EPCLUSA, monitoring of certain laboratory parameters and/or concomitant medications may be required. For guidance see **DRUG INTERACTIONS, Drug-Drug Interactions, Other Forms of Interactions**.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

The overall safety profile of EPCLUSA was established in the following patient populations: non-cirrhotic and cirrhotic (compensated and decompensated) adult patients infected with HCV; adult patients co-infected with HIV-1 (without cirrhosis or with compensated cirrhosis); and pediatric patients  $\geq 12$  years of age without decompensated cirrhosis.

The safety assessment of EPCLUSA was based on pooled Phase 3 clinical trial data (ASTRAL-1, ASTRAL-2, and ASTRAL-3) from adult patients with HCV without cirrhosis or with compensated cirrhosis including 1035 patients who received EPCLUSA for 12 weeks. The proportion of patients who permanently discontinued treatment due to adverse events was 0.2% for patients receiving EPCLUSA for 12 weeks. Of the 1035 patients, 2% had at least one serious



adverse event (SAE), with no patients experiencing a treatment-related SAE.

The safety of EPCLUSA was also assessed in adult patients with decompensated cirrhosis (Child-Pugh B) in one Phase 3 trial (ASTRAL-4). In ASTRAL-4, the proportion of patients who permanently discontinued treatment due to adverse events was 5% (4/87) for those patients treated with EPCLUSA + RBV for 12 weeks, 1% (1/90) for those patients treated with EPCLUSA for 12 weeks, and 4% (4/90) for those patients treated with EPCLUSA for 24 weeks. Serious adverse events occurred in 19% (17/90), 16% (14/87) and 18% (16/90) of patients treated with EPCLUSA for 12 weeks, EPCLUSA + RBV for 12 weeks and EPCLUSA for 24 weeks, respectively. One patient (0.4%) experienced SAEs considered related to EPCLUSA.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Adult Patients without Cirrhosis and Patients with Compensated Cirrhosis**

The adverse reactions (Grades 2 to 4) observed in  $\geq 2\%$  of patients receiving 12 weeks of treatment with EPCLUSA in clinical trials are listed in Table 1.

**Table 1. Adverse Reactions (Grades 2-4) Reported in  $\geq 2\%$  of Patients Receiving 12 Weeks of EPCLUSA<sup>a</sup> from the Pooled Phase 3 Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)**

	<b>EPCLUSA 12 Weeks N = 1035</b>	<b>Placebo 12 Weeks N = 116</b>
Headache	4%	3%
Fatigue	3%	1%

a. Frequencies of adverse reactions are based on treatment-emergent adverse events, considered related to study drug by site investigators.

### **Less Common Clinical Trial Adverse Drug Reactions (< 2%)**

Adverse reactions (Grades 2 to 4) occurring in less than 2% of patients receiving 12 weeks of treatment with EPCLUSA in clinical trials are listed below by body system:

**Table 2. Adverse Reactions (Grades 2-4) Reported in < 2% of Patients Receiving 12 Weeks of EPCLUSA<sup>a</sup> from the Pooled Phase 3 Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)**

<b>Body System</b>	<b>EPCLUSA 12 Weeks</b>
<b>Blood and Lymphatic System Disorders</b>	Leukopenia
<b>Cardiac Disorders</b>	Palpitations
<b>Ear and Labyrinth Disorders</b>	Vertigo
<b>Gastrointestinal Disorders</b>	Abdominal distension, abdominal pain, abdominal pain upper, constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastroesophageal reflux disease, nausea, stomatitis, tongue coated, toothache, vomiting
<b>General Disorders and Administration Site Conditions</b>	Asthenia, chest pain, edema peripheral, influenza like illness, pain, pyrexia
<b>Infections and Infestations</b>	Lower respiratory tract infection, nasopharyngitis, sinusitis
<b>Investigations</b>	Electrocardiogram QT prolonged, weight decreased
<b>Metabolism and Nutrition Disorders</b>	Decreased appetite, gout, increased appetite
<b>Musculoskeletal and Connective Tissue Disorders</b>	Arthralgia, back pain, muscle spasms, musculoskeletal pain, myalgia, neck pain, osteoarthritis, pain in extremity, spinal pain, tendon pain
<b>Nervous System Disorders</b>	Disturbance in attention, dizziness, dysgeusia, migraine, psychomotor hyperactivity, somnolence
<b>Psychiatric Disorders</b>	Anxiety, apathy, attention deficit/hyperactivity disorder, confusional state, depressed mood, depression, insomnia, irritability, loss of libido, mood swings, sleep disorder
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	Cough, dyspnoea, epistaxis, oropharyngeal pain
<b>Skin and Subcutaneous Tissue Disorders</b>	Alopecia, eczema, pruritus, pruritus generalised, rash, rash pruritic
<b>Vascular Disorders</b>	Hypertension, hypertensive crisis, hypotension

a. Frequencies of adverse reactions are based on treatment-emergent adverse events, considered related to study drug by site investigators.

### **Abnormal Hematologic and Clinical Chemistry Findings**

The frequency of treatment-emergent laboratory abnormalities (Grades 2-4) occurring in at least 2% of patients receiving 12 weeks of treatment with EPCLUSA are described in Table 3.

**Table 3. Laboratory Abnormalities (Grades 2-4) Reported in  $\geq 2\%$  of Patients Receiving 12 Weeks of EPCLUSA from the Pooled Phase 3 Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)**

Laboratory Abnormality Parameters	EPCLUSA 12 Weeks	Placebo 12 Weeks
	N = 1035	N = 116
<b>Chemistry</b>		
Hyperglycemia ( $> 8.91$ mmol/L)	11%	12%
Hypoglycemia ( $< 3.03$ mmol/L)	2%	$< 1\%$
Lipase ( $> 1.5 \times$ ULN)	8%	4%
<b>Hematology</b>		
Platelets ( $< 100 \times 10^9/L$ )	2%	4%

ULN = Upper Limit of Normal

**Adult Patients with Decompensated Cirrhosis**

The adverse reactions (Grades 2 to 4) observed in  $\geq 2\%$  of patients receiving 12 or 24 weeks of treatment with EPCLUSA or 12 weeks of treatment with EPCLUSA plus ribavirin in the ASTRAL-4 study are listed in Table 4.

**Table 4. Adverse Reactions (Grades 2-4) Reported in  $\geq 2\%$  of Patients Receiving 12 or 24 Weeks of EPCLUSA<sup>a</sup> without Ribavirin or 12 Weeks of EPCLUSA with Ribavirin in ASTRAL-4**

	EPCLUSA 12 Weeks	EPCLUSA + RBV 12 Weeks	EPCLUSA 24 Weeks
	N = 90	N = 87	N = 90
Anemia	0	14%	0
Decreased appetite	0	0	3%
Diarrhea	0	2%	0
Dyspnea	0	3%	0
Fatigue	2%	8%	3%
Headache	7%	1%	1%
Insomnia	0	2%	1%
Rash	1%	2%	0

a. Frequencies of adverse reactions are based on treatment-emergent adverse events, considered related to study drug by site investigators.

**Less Common Clinical Trial Adverse Drug Reactions ( $< 2\%$ )**

Adverse reactions (Grades 2 to 4) occurring in less than 2% of patients receiving 12 or 24 weeks of EPCLUSA or 12 weeks of EPCLUSA with ribavirin in ASTRAL-4 are listed below by body system:

**Table 5. Adverse Reactions (Grades 2-4) Reported in < 2% of Patients Receiving 12 or 24 Weeks of EPCLUSA<sup>a</sup> or 12 Weeks of EPCLUSA with Ribavirin from ASTRAL-4**

<b>Body System</b>	<b>EPCLUSA 12 Weeks</b>	<b>EPCLUSA + RBV 12 Weeks</b>	<b>EPCLUSA 24 Weeks</b>
<b>Cardiac Disorders</b>	N/A	Palpitations	N/A
<b>Gastrointestinal Disorders</b>	Vomiting	Vomiting	Abdominal discomfort, abdominal pain upper, gastroesophageal reflux disease
<b>General Disorders and Administration Site Conditions</b>	N/A	Asthenia	N/A
<b>Hepatobiliary Disorders</b>	N/A	N/A	Hepatorenal syndrome
<b>Infections and Infestations</b>	N/A	N/A	Peritonitis, sepsis
<b>Investigations</b>	N/A	N/A	Weight decreased
<b>Metabolism and Nutrition Disorders</b>	N/A	N/A	Diabetes mellitus
<b>Musculoskeletal and Connective Tissue Disorders</b>	Arthralgia	N/A	N/A
<b>Nervous System Disorders</b>	N/A	Headache, tremor	Headache, poor quality sleep
<b>Psychiatric Disorders</b>	Anxiety, depression	N/A	Anxiety, insomnia
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	N/A	Dyspnea exertional	N/A
<b>Skin and Subcutaneous Tissue Disorders</b>	Rash	Pruritus, rash pruritic	Dermatitis contact
<b>Vascular Disorders</b>	N/A	Hypertension	Hypotension

N/A = Not applicable

- a. Frequencies of adverse reactions are based on treatment-emergent adverse events, considered related to study drug by site investigators.

### **Abnormal Hematologic and Clinical Chemistry Findings**

The frequency of treatment-emergent laboratory abnormalities (Grades 2-4) occurring in at least 2% of patients receiving 12 or 24 weeks of treatment with EPCLUSA or 12 weeks of treatment with EPCLUSA + RBV are described in Table 6 below.

**Table 6. Laboratory Abnormalities (Grades 2-4) Reported in  $\geq 2\%$  of Patients Receiving 12 or 24 Weeks of EPCLUSA or 12 Weeks of EPCLUSA with Ribavirin from ASTRAL-4**

Laboratory Abnormality Parameters	EPCLUSA 12 Weeks	EPCLUSA + RBV 12 Weeks	EPCLUSA 24 Weeks
	N = 90	N = 87	N = 90
<b>Chemistry</b>			
Albumin (< 30 g/L)	14%	13%	17%
Alkaline phosphatase (> 2.5 x ULN)	2%	1%	0
Amylase (> 1.5 x ULN)	4%	6%	10%
AST (> 2.5 x ULN)	2%	1%	4%
Creatine kinase ( $\geq 6$ x ULN)	4%	2%	3%
GGT (> 2.5 x ULN)	3%	0	3%
Hyperbilirubinemia (> 1.5 x ULN)	18%	54%	13%
Hyperglycemia (> 8.91 mmol/L)	42%	47%	47%
Hypokalemia (< 3.0 mmol/L)	2%	2%	1%
Hypoglycemia (< 3.03 mmol/L)	3%	0	7%
Hyponatremia (< 130 mmol/L)	8%	8%	9%
Lipase (> 1.5 x ULN)	29%	29%	30%
<b>Hematology</b>			
Hemoglobin (< 100 g/L)	9%	24%	11%
INR (> 1.5 x ULN)	1%	0	2%
Lymphocytes (< 0.6 x 10 <sup>9</sup> /L)	20%	38%	23%
Neutrophils (< 1.0 x 10 <sup>9</sup> /L)	3%	5%	9%
Platelets (< 100 x 10 <sup>9</sup> /L)	27%	31%	37%
White blood cells (< 2.0 x 10 <sup>9</sup> /L)	4%	13%	7%

ULN = Upper Limit of Normal

Among patients with decompensated cirrhosis in the ASTRAL-4 trial, direct bilirubin was found to remain stable ( $< 17.1 \mu\text{mol/L}$  change from baseline throughout treatment) in the majority of patients. One patient randomized to receive 24 weeks of treatment with EPCLUSA had a  $> 17.1 \mu\text{mol/L}$  increase from baseline in direct bilirubin from Week 6 through Week 10 for which no clinical explanation could be identified; this patient completed 24 weeks of treatment.

### **Adult Patients with HCV/HIV-1 Co-infection**

The safety of EPCLUSA was assessed in an open-label trial of 106 patients with HCV/HIV-1 co-infection who were on stable antiretroviral therapy (see **CLINICAL TRIALS**). The safety profile in HCV/HIV-1 co-infected patients was similar to that observed in HCV mono-infected patients treated with EPCLUSA. The most common adverse reactions occurring in at least 10% of patients were fatigue (22%) and headache (10%). No adverse drug reactions specific to EPCLUSA were identified.

### **Adult Patients with Renal Impairment**

The safety of EPCLUSA was assessed in an open-label trial (Study GS-US-342-4062) of 59 patients with HCV and end stage renal disease (ESRD) requiring dialysis who received EPCLUSA for 12 weeks (see **CLINICAL TRIALS**). The adverse events observed were consistent with expected clinical sequelae of ESRD. No adverse reactions specific to EPCLUSA were identified.

### **Pediatric Patients ( $\geq 12$ Years of Age)**

The safety of EPCLUSA in pediatric patients  $\geq 12$  years of age was assessed in an open-label trial (Study GS-US-342-1143, Cohort 1) of 102 patients who were treated with EPCLUSA for 12 weeks. The adverse reactions observed were consistent with those observed in clinical trials of EPCLUSA in adults (see **CLINICAL TRIALS**).

The safety of EPCLUSA in pediatric patients with renal impairment or co-infected with HIV-1 has not been studied.

### **Post-Market Adverse Drug Reactions**

In addition to adverse reactions from clinical studies, the following adverse reactions have been identified during post-approval use of sofosbuvir or EPCLUSA. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

#### **Cardiac Disorders**

Serious symptomatic bradycardia when amiodarone is coadministered with sofosbuvir in combination with another HCV DAA (see **WARNINGS AND PRECAUTIONS, Cardiovascular** and **DRUG INTERACTIONS**).

## **Skin and Subcutaneous Tissue Disorders**

Skin rashes (sometimes with blisters or angioedema-like swelling) and angioedema.

## **DRUG INTERACTIONS**

### **Overview**

As EPCLUSA contains sofosbuvir and velpatasvir, any interactions that have been identified with these agents individually may occur with EPCLUSA.

After oral administration of EPCLUSA, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction. In clinical pharmacology studies, both sofosbuvir and the primary circulating metabolite GS-331007 (dephosphorylated nucleotide metabolite) were monitored for purposes of pharmacokinetic analyses.

### **Drug-Drug Interactions**

#### **Potential for EPCLUSA to Affect Other Drugs**

Velpatasvir is an inhibitor of drug transporter P-gp, breast cancer resistance protein (BCRP), OATP1B1 and OATP1B3. Coadministration of EPCLUSA with drugs that are substrates of these transporters may increase the exposure of such drugs. The drug-drug interaction potential of velpatasvir is limited to the presystemic processes (intestinal efflux and hepatic uptake); clinically relevant interactions in systemic circulation are not expected.

At clinically relevant concentration, velpatasvir is not an inhibitor of hepatic transporters OATP1A2 or OCT1, renal transporters OCT2, OAT1, OAT3 or MATE1, or CYP or UGT1A1 enzymes.

Sofosbuvir and GS-331007 are not relevant inhibitors of efflux drug transporters P-gp, BCRP, renal efflux transporter MRP2, hepatic efflux transporter BSEP, hepatic uptake transporters OATP1B1, OATP1B3, OCT1, and GS-331007 is not an inhibitor of renal uptake transporters OAT1, OCT2 and renal efflux transporter MATE1. Sofosbuvir and GS-331007 are not inhibitors or inducers of CYP or UGT1A1 enzymes.

#### **Potential for Other Drugs to Affect EPCLUSA**

Sofosbuvir and velpatasvir are substrates of efflux drug transporters P-gp and BCRP while GS-331007 is not. GS-331007 is not a substrate for renal transporters including organic anion transporter OAT1 or OAT3, or organic cation transporter OCT2. Velpatasvir is poorly transported by OATP1B1 and OATP1B3. *In vitro*, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed.

Drugs that are P-gp inducers and/or moderate to strong inducers of CYP2B6, CYP2C8, or CYP3A4 (eg, rifampin, St. John's wort or carbamazepine) may significantly decrease plasma concentrations of sofosbuvir and/or velpatasvir leading to reduced therapeutic effect of

EPCLUSA. The use of these agents with EPCLUSA is not recommended (see **WARNINGS AND PRECAUTIONS**).

Coadministration with drugs that inhibit P-gp and/or BCRP may increase sofosbuvir and/or velpatasvir plasma concentrations without increasing GS-331007 plasma concentration. Drugs that inhibit CYP2B6, CYP2C8, or CYP3A4 may increase plasma concentration of velpatasvir. EPCLUSA may be coadministered with P-gp, BCRP, and CYP inhibitors.

Table 7 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either EPCLUSA, the components of EPCLUSA (sofosbuvir and velpatasvir) as individual agents, or are predicted drug interactions that may occur with EPCLUSA. The table is not all-inclusive (see **ACTION AND CLINICAL PHARMACOLOGY**).

**Table 7. Established and Other Potentially Significant<sup>a</sup> Drug Interactions**

<b>Concomitant Drug Class: Drug Name</b>	<b>Effect on Concentration<sup>b</sup></b>	<b>Clinical Comment</b>
<b>Acid Reducing Agents:</b>	↓ velpatasvir	Velpatasvir solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease concentration of velpatasvir.
Antacids (eg, aluminum and magnesium hydroxide)		It is recommended to separate antacid and EPCLUSA administration by 4 hours.
H <sub>2</sub> -receptor antagonists <sup>c</sup> (eg, famotidine)		H <sub>2</sub> -receptor antagonists may be administered simultaneously with or staggered from EPCLUSA at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.
Proton-pump inhibitors <sup>c</sup> (eg, omeprazole)		Proton-pump inhibitor doses comparable with omeprazole 20 mg or lower can be administered with EPCLUSA when EPCLUSA is administered with food.
<b>Antiarrhythmics:</b> amiodarone	Effect on amiodarone, sofosbuvir and velpatasvir concentrations unknown	Coadministration of amiodarone with EPCLUSA may result in serious symptomatic bradycardia. The mechanism of this effect is unknown. Coadministration of amiodarone with EPCLUSA is not recommended; if coadministration is required, cardiac monitoring is recommended (see <b>WARNINGS AND PRECAUTIONS, Cardiovascular</b> and <b>ADVERSE REACTIONS, Post-Market Adverse Drug Reactions</b> ).
digoxin <sup>c</sup>	↑ digoxin	Coadministration of EPCLUSA with digoxin may increase the concentration of digoxin due to intestinal inhibition of P-gp by velpatasvir. Caution is warranted and therapeutic concentration monitoring of digoxin is recommended when coadministered with EPCLUSA.
<b>Anticonvulsants:</b> carbamazepine phenytoin phenobarbital oxcarbazepine	↓ sofosbuvir ↓ velpatasvir	Coadministration of EPCLUSA with carbamazepine, phenytoin, phenobarbital, or oxcarbazepine is expected to decrease the concentration of sofosbuvir and/or velpatasvir, leading to reduced therapeutic effect of EPCLUSA. Coadministration is not recommended.



<b>Concomitant Drug Class: Drug Name</b>	<b>Effect on Concentration<sup>b</sup></b>	<b>Clinical Comment</b>
<b>Antimicrobials:</b> rifabutin rifampin <sup>c</sup> rifapentine*	↓ sofosbuvir ↓ velpatasvir	Coadministration of EPCLUSA with rifabutin, rifampin, or rifapentine is expected to decrease the concentration of sofosbuvir and/or velpatasvir, leading to reduced therapeutic effect of EPCLUSA. Coadministration is not recommended.
<b>Antiretrovirals:</b> efavirenz <sup>c</sup>  Regimens containing tenofovir disoproxil fumarate <sup>c</sup> (tenofovir DF)	↓ velpatasvir  ↑ tenofovir	Coadministration of EPCLUSA with efavirenz is expected to decrease the concentration of velpatasvir. Coadministration of EPCLUSA with efavirenz-containing regimens is not recommended. EPCLUSA has been shown to increase tenofovir exposure. Patients receiving tenofovir DF and EPCLUSA concomitantly should be monitored for adverse reactions associated with tenofovir DF. Refer to the Product Monographs for tenofovir DF-containing products for recommendations on renal monitoring.
<b>HMG-CoA Reductase Inhibitors:</b> rosuvastatin <sup>c</sup>	↑ rosuvastatin	Coadministration of EPCLUSA with rosuvastatin may increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with EPCLUSA at a dose that does not exceed 10 mg.
atorvastatin <sup>c</sup>	↑ atorvastatin	Coadministration of EPCLUSA with atorvastatin may be associated with increased risk of myopathy, including rhabdomyolysis. Monitor closely for HMG-CoA reductase inhibitor-associated adverse reactions, such as myopathy and rhabdomyolysis.

\*Drug not marketed in Canada.

- This table is not all-inclusive.
- ↑ = increase, ↓ = decrease, ↔ = no effect.
- These interactions have been studied in healthy adults.

### Drugs without Clinically Significant Interactions with EPCLUSA

Based on drug interaction studies conducted with the components of EPCLUSA (sofosbuvir or velpatasvir) or EPCLUSA, no clinically significant drug interactions have either been observed or are expected when EPCLUSA is used with the following drugs: atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, dolutegravir, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, emtricitabine, ketoconazole, lopinavir/ritonavir, methadone, oral contraceptives, pravastatin, raltegravir, rilpivirine or tacrolimus (see **DRUG INTERACTIONS, Other Forms of Interactions, Assessment of Drug Interactions** and **WARNINGS AND PRECAUTIONS**).

### Other Forms of Interactions

As liver function may improve due to treatment of HCV with DAAs, it is recommended to closely monitor:

- the International Normalized Ratio [INR] in patients taking vitamin K antagonists,
- blood glucose levels in diabetic patients,
- immunosuppressive drug levels (e.g., calcineurin inhibitors cyclosporine and tacrolimus)

in patients receiving immunosuppressive therapy,

- other relevant laboratory parameters in susceptible patients and/or other concomitant medications significantly affected by changes in hepatic function.

The dose of vitamin K antagonists, anti-diabetic agents, immunosuppressive agents, or other concomitant medications significantly affected by changes in hepatic function should be modified when necessary.

### **Assessment of Drug Interactions**

The effects of coadministered drugs on the exposure of sofosbuvir, GS-331007 and velpatasvir are shown in Table 8. The effects of sofosbuvir, velpatasvir or EPCLUSA on the exposure of coadministered drugs are shown in Table 9.

**Table 8. Drug Interactions: Changes in Pharmacokinetic Parameters for Sofosbuvir and the Predominant Circulating Metabolite GS-331007, and Velpatasvir in the Presence of the Coadministered Drug<sup>a</sup>**

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
<b>Antibiotic</b>								
Rifampin <sup>f</sup>	600 once daily	400 single dose	ND	17	sofosbuvir	0.23 (0.19, 0.29)	0.28 (0.24, 0.32)	NA
					GS-331007	1.23 (1.14, 1.34)	0.95 (0.88, 1.03)	NA
	600 single dose	ND	100 single dose	12	velpatasvir	0.29 (0.23, 0.37)	0.18 (0.15, 0.22)	NA
					velpatasvir	1.28 (1.05, 1.56)	1.46 (1.17, 1.83)	NA
<b>Anticonvulsants</b>								
Carbamazepine	300 twice daily	400 single dose	ND	24	sofosbuvir	0.52 (0.43, 0.62)	0.52 (0.46, 0.59)	NA
					GS-331007	1.04 (0.97, 1.11)	0.99 (0.94, 1.04)	NA
<b>Antimycobacterials</b>								
Rifabutin	300 once daily	400 single dose	ND	20	sofosbuvir	0.64 (0.53, 0.77)	0.76 (0.63, 0.91)	NA

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
					GS-331007	1.15 (1.03, 1.27)	1.03 (0.95, 1.12)	NA
<b>Anti-HIV Drugs</b>								
Atazanavir/ ritonavir + emtricitabine/ tenofovir DF	300/100 + 200/300 once daily	400 once daily	100 once daily	24	sofosbuvir	1.12 (0.97, 1.29)	1.22 (1.12, 1.33)	NA
					GS-331007	1.21 (1.12, 1.29)	1.32 (1.27, 1.36)	1.42 (1.37, 1.49)
					velpatasvir	1.55 (1.41, 1.71)	2.42 (2.23, 2.64)	4.01 (3.57, 4.50)
Darunavir/ ritonavir + emtricitabine/ tenofovir DF	800/100 + 200/300 once daily	400 once daily	100 once daily	29	sofosbuvir	0.62 (0.54, 0.71)	0.72 (0.66, 0.80)	NA
					GS-331007	1.04 (0.99, 1.08)	1.13 (1.08, 1.18)	1.13 (1.06, 1.19)
					velpatasvir	0.76 (0.65, 0.89)	0.84 (0.72, 0.98)	1.01 (0.87, 1.18)
Dolutegravir	50 once daily	400 once daily	100 once daily	24	sofosbuvir	0.88 (0.80, 0.98)	0.92 (0.85, 0.99)	NA
					GS-331007	1.01 (0.93, 1.10)	0.99 (0.97, 1.01)	0.99 (0.97, 1.01)
					velpatasvir	0.94 (0.86, 1.02)	0.91 (0.84, 0.98)	0.88 (0.82, 0.94)
Efavirenz/ emtricitabine/ tenofovir DF <sup>b</sup>	600/200/300 once daily	400 once daily	100 once daily	14	sofosbuvir	1.38 (1.14, 1.67)	0.97 (0.83, 1.14)	NA
					GS-331007	0.86 (0.80, 0.93)	0.90 (0.85, 0.96)	1.01 (0.95, 1.07)
					velpatasvir	0.53 (0.43, 0.64)	0.47 (0.39, 0.57)	0.43 (0.36, 0.52)
Elvitegravir/ cobicistat/ emtricitabine/	150/150/200/10 once daily	400 once daily	100 once daily	24	sofosbuvir	1.23 (1.07, 1.42)	1.37 (1.24, 1.52)	NA

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
tenofovir alafenamide <sup>c</sup>					GS-331007	1.29 (1.25, 1.33)	1.48 (1.43, 1.53)	1.58 (1.52, 1.65)
					velpatasvir	1.30 (1.17, 1.45)	1.50 (1.35, 1.66)	1.60 (1.44, 1.78)
					sofosbuvir	1.01 (0.85, 1.19)	1.24 (1.13, 1.37)	NA
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir DF <sup>d</sup>	150/150/200/ 300 once daily	400 once daily	100 once daily	24	GS-331007	1.13 (1.07, 1.18)	1.35 (1.30, 1.40)	1.45 (1.38, 1.52)
					velpatasvir	1.05 (0.93, 1.19)	1.19 (1.07, 1.34)	1.37 (1.22, 1.54)
					sofosbuvir	1.09 (0.95, 1.25)	1.16 (1.09, 1.24)	NA
Emtricitabine/ rilpivirine/ tenofovir DF <sup>e</sup>	200/25/300 once daily	400 once daily	100 once daily	24	GS-331007	0.96 (0.90, 1.01)	1.04 (1.00, 1.07)	1.12 (1.07, 1.17)
					velpatasvir	0.96 (0.85, 1.10)	0.99 (0.88, 1.11)	1.02 (0.91, 1.15)
					sofosbuvir	0.59 (0.49, 0.71)	0.71 (0.64, 0.78)	NA
Lopinavir/ ritonavir + emtricitabine/ tenofovir DF	4 x 200/50 + 200/300 once daily	400 once daily	100 once daily	24	GS-331007	1.01 (0.98, 1.05)	1.15 (1.09, 1.21)	1.15 (1.07, 1.25)
					velpatasvir	0.70 (0.59, 0.83)	1.02 (0.89, 1.17)	1.63 (1.43, 1.85)
					sofosbuvir	1.09 (0.97, 1.23)	1.16 (1.07, 1.25)	NA
Raltegravir + emtricitabine/ tenofovir DF	400 twice daily+ 200/300 once daily	400 once daily	100 once daily	30	GS-331007	0.95 (0.91, 0.98)	1.03 (1.00, 1.06)	1.08 (1.04, 1.13)
					velpatasvir	0.97 (0.87, 1.08)	0.98 (0.88, 1.10)	0.97 (0.87, 1.07)
					sofosbuvir	1.09 (0.97, 1.23)	1.16 (1.07, 1.25)	NA

**Azole Anti-fungal**

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
Ketoconazole <sup>f</sup>	200 twice daily	ND	100 single dose	12	velpatasvir	1.29 (1.02, 1.64)	1.71 (1.35, 2.18)	NA

**H<sub>2</sub>-Receptor Antagonists**

Famotidine	40 single dose simultaneously with EPCLUSA	400 single dose	100 single dose	60	sofosbuvir	0.92 (0.82, 1.05)	0.82 (0.74, 0.91)	NA
					GS-331007	0.84 (0.78, 0.89)	0.94 (0.91, 0.98)	NA
					velpatasvir	0.80 (0.70, 0.91)	0.81 (0.71, 0.91)	NA
	40 single dose 12 hours prior to EPCLUSA			60	sofosbuvir	0.77 (0.68, 0.87)	0.80 (0.73, 0.88)	NA
					GS-331007	1.20 (1.13, 1.28)	1.04 (1.01, 1.08)	NA
					velpatasvir	0.87 (0.76, 1.00)	0.85 (0.74, 0.97)	NA

**Immunosuppressants**

Cyclosporine <sup>f</sup>	600 single dose	400 single dose	ND	19	sofosbuvir	2.54 (1.87, 3.45)	4.53 (3.26, 6.30)	NA
					GS-331007	0.60 (0.53, 0.69)	1.04 (0.90, 1.20)	NA
		ND	100 single dose	12	velpatasvir	1.56 (1.22, 2.01)	2.03 (1.51, 2.71)	NA
Tacrolimus <sup>f</sup>	5 single dose	400 single dose	ND	16	sofosbuvir	0.97 (0.65, 1.43)	1.13 (0.81, 1.57)	NA
					GS-331007	0.97 (0.83, 1.14)	1.00 (0.87, 1.13)	NA

**Opiate Agonist**

Methadone <sup>f</sup>	30 to 130 daily	400 once daily	ND	14	sofosbuvir	0.95 (0.68, 1.33)	1.30 (1.00, 1.69)	NA
------------------------	-----------------	----------------	----	----	------------	----------------------	----------------------	----

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
					GS-331007	0.73 (0.65, 0.83)	1.04 (0.89, 1.22)	NA

**Proton-Pump Inhibitors**

Omeprazole	20 once daily simultaneously with EPCLUSA	400 single dose fasted	100 single dose fasted	60	sofosbuvir	0.66 (0.55, 0.78)	0.71 (0.60, 0.83)	NA
					GS-331007	1.18 (1.10, 1.26)	1.00 (0.95, 1.05)	NA
					velpatasvir	0.63 (0.50, 0.78)	0.64 (0.52, 0.79)	NA
	20 once daily 12 hours prior to EPCLUSA	400 single dose fasted	100 single dose fasted	60	sofosbuvir	0.55 (0.47, 0.64)	0.56 (0.49, 0.65)	NA
					GS-331007	1.26 (1.18, 1.34)	0.97 (0.94, 1.01)	NA
					velpatasvir	0.43 (0.35, 0.54)	0.45 (0.37, 0.55)	NA
	20 once daily 2 hours prior to EPCLUSA	400 single dose fed	100 single dose fed	40	sofosbuvir	0.84 (0.68, 1.03)	1.08 (0.94, 1.25)	NA
					GS-331007	0.94 (0.88, 1.02)	0.99 (0.96, 1.03)	NA
					velpatasvir	0.52 (0.43, 0.64)	0.62 (0.51, 0.75)	NA
	20 once daily 4 hours after EPCLUSA	400 single dose fed	100 single dose fed	38	sofosbuvir	0.79 (0.68, 0.92)	1.05 (0.94, 1.16)	NA
					GS-331007	0.91 (0.85, 0.98)	0.99 (0.95, 1.02)	NA
					velpatasvir	0.67 (0.58, 0.78)	0.74 (0.63, 0.86)	NA
40 once daily 4 hours after EPCLUSA	400 single dose fed	100 single dose fed	40	sofosbuvir	0.70 (0.57, 0.87)	0.91 (0.76, 1.08)	NA	
				GS-331007	1.01 (0.96, 1.07)	0.99 (0.94, 1.03)	NA	

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir Dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Sofosbuvir, GS-331007 and Velpatasvir PK with/without Coadministered Drug No Effect = 1.00			
						C <sub>max</sub>	AUC	C <sub>min</sub>
					velpatasvir	0.44 (0.34, 0.57)	0.47 (0.37, 0.60)	NA

NA = not available/not applicable; ND = not dosed

- All interaction studies conducted in healthy volunteers.
- Administered as ATRIPLA® (efavirenz/emtricitabine/tenofovir DF fixed-dose combination).
- Administered as GENVOYA® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose single tablet regimen).
- Administered as STRIBILD® (elvitegravir/cobicistat/emtricitabine/tenofovir DF fixed-dose single tablet regimen).
- Administered as COMPLERA® (emtricitabine/rilpivirine/tenofovir DF fixed-dose combination).
- These studies have not been performed with EPCLUSA; they were conducted with either sofosbuvir or velpatasvir administered as single agents.

**Table 9. Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Sofosbuvir, Velpatasvir, or EPCLUSA<sup>a</sup>**

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir, Velpatasvir or EPCLUSA No Effect=1.00		
					C <sub>max</sub>	AUC	C <sub>min</sub>
<b>Anti-HIV</b>							
Atazanavir/ritonavir + emtricitabine/tenofovir DF <sup>b</sup>	Atazanavir 300 once daily	400 once daily	100 once daily	24	1.09 (1.00, 1.19)	1.20 (1.10, 1.31)	1.39 (1.20, 1.61)
	Ritonavir 100 once daily				0.89 (0.82, 0.97)	0.97 (0.89, 1.05)	1.29 (1.15, 1.44)
	Emtricitabine 200 once daily				1.01 (0.96, 1.06)	1.02 (0.99, 1.04)	1.06 (1.02, 1.11)
	Tenofovir DF 300 once daily				1.55 (1.43, 1.68)	1.30 (1.24, 1.36)	1.39 (1.31, 1.48)
Darunavir/ritonavir + emtricitabine/tenofovir DF <sup>c</sup>	Darunavir 800 once daily	400 once daily	100 once daily	29	0.90 (0.86, 0.95)	0.92 (0.87, 0.98)	0.87 (0.79, 0.95)
	Ritonavir 100 once daily				1.07 (0.97, 1.17)	1.12 (1.05, 1.19)	1.09 (1.02, 1.15)
	Emtricitabine 200 once daily				1.05 (1.01, 1.08)	1.05 (1.02, 1.08)	1.04 (0.98, 1.09)
	Tenofovir DF 300 once daily				1.55 (1.45, 1.66)	1.39 (1.33, 1.44)	1.52 (1.45, 1.59)
Dolutegravir	50 once daily	400 once daily	100 once daily	24	1.06 (1.01, 1.11)	1.06 (1.01, 1.13)	1.04 (0.98, 1.10)

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir, Velpatasvir or EPCLUSA No Effect=1.00		
					C <sub>max</sub>	AUC	C <sub>min</sub>
Efavirenz/ emtricitabine/ tenofovir DF <sup>d</sup>	Efavirenz 600 once daily	400 once daily	100 once daily	15	0.81 (0.74, 0.89)	0.85 (0.80, 0.91)	0.90 (0.85, 0.95)
	Emtricitabine 200 once daily				1.07 (0.98, 1.18)	1.07 (1.00, 1.14)	1.10 (0.97, 1.25)
	Tenofovir DF 300 once daily				1.77 (1.53, 2.04)	1.81 (1.68, 1.94)	2.21 (2.00, 2.43)
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide <sup>e</sup>	Elvitegravir 150 once daily	400 once daily	100 once daily	24	0.87 (0.80, 0.94)	0.94 (0.88, 1.00)	1.08 (0.97, 1.20)
	Cobicistat 150 once daily				1.16 (1.09, 1.23)	1.30 (1.23, 1.38)	2.03 (1.67, 2.48)
	Emtricitabine 200 once daily				1.02 (0.97, 1.06)	1.01 (0.98, 1.04)	1.02 (0.97, 1.07)
	Tenofovir alafenamide 10 once daily				0.80 (0.68, 0.94)	0.87 (0.81, 0.94)	NA
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir DF <sup>f</sup>	Elvitegravir 150 once daily	400 once daily	100 once daily	24	0.93 (0.86, 1.00)	0.93 (0.87, 0.99)	0.97 (0.91, 1.04)
	Cobicistat 150 once daily				1.11 (1.06, 1.17)	1.23 (1.17, 1.29)	1.71 (1.54, 1.90)
	Emtricitabine 200 once daily				1.02 (0.97, 1.08)	1.01 (0.98, 1.04)	1.06 (1.01, 1.11)
	Tenofovir DF 300 once daily				1.36 (1.25, 1.47)	1.35 (1.29, 1.42)	1.45 (1.39, 1.51)
Emtricitabine/ rilpivirine/ tenofovir DF <sup>g</sup>	Emtricitabine 200 once daily	400 once daily	100 once daily	24	0.95 (0.90, 1.00)	0.99 (0.97, 1.02)	1.05 (0.99, 1.11)
	Rilpivirine 25 once daily				0.93 (0.88, 0.98)	0.95 (0.90, 1.00)	0.96 (0.90, 1.03)
	Tenofovir DF 300 once daily				1.44 (1.33, 1.55)	1.40 (1.34, 1.46)	1.84 (1.76, 1.92)
Lopinavir/ritonavir + emtricitabine/ tenofovir DF	Lopinavir 200 x 4 once daily	400 once daily	100 once daily	24	0.97 (0.92, 1.02)	1.00 (0.93, 1.06)	1.11 (0.96, 1.30)
	Ritonavir 50 x 4 once daily				0.94 (0.83, 1.07)	0.97 (0.89, 1.05)	1.07 (0.95, 1.20)
	Emtricitabine 200 once daily				1.02 (0.93, 1.12)	1.00 (0.94, 1.06)	0.97 (0.91, 1.04)
	Tenofovir DF 300 once daily				1.42 (1.27, 1.57)	1.22 (1.14, 1.31)	1.28 (1.20, 1.37)
Raltegravir + emtricitabine/	Emtricitabine 200 once daily	400 once daily	100 once daily	30	1.08 (1.04, 1.12)	1.05 (1.03, 1.07)	1.02 (0.97, 1.08)



Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir, Velpatasvir or EPCLUSA No Effect=1.00		
					C <sub>max</sub>	AUC	C <sub>min</sub>
tenofovir DF	Tenofovir DF 300 once daily				1.46 (1.39, 1.54)	1.40 (1.34, 1.45)	1.70 (1.61, 1.79)
	Raltegravir 400 twice daily				1.03 (0.74, 1.43)	0.97 (0.73, 1.28)	0.79 (0.42, 1.48)
<b>Cardiac Glycoside</b>							
Digoxin	0.25 single dose	ND	100 once daily	21	1.88 (1.71, 2.08)	1.34 (1.13, 1.60)	NA
<b>Estrogen-based Contraceptives</b>							
Norelgestromin <sup>h</sup>	Norgestimate 0.180/0.215/0.250/ethinyl estradiol 0.025 once daily	ND	100 once daily	13	0.97 (0.88, 1.07)	0.90 (0.82, 0.98)	0.92 (0.83, 1.03)
		400 once daily	ND	15	1.07 (0.94, 1.22)	1.06 (0.92, 1.21)	1.07 (0.89, 1.28)
Norgestrel <sup>h</sup>		ND	100 once daily	13	0.96 (0.78, 1.19)	0.91 (0.73, 1.15)	0.92 (0.73, 1.18)
		400 once daily	ND	15	1.18 (0.99, 1.41)	1.19 (0.98, 1.45)	1.23 (1.00, 1.51)
Ethinyl estradiol <sup>h</sup>		ND	100 once daily	12	1.39 (1.17, 1.66)	1.04 (0.87, 1.24)	0.83 (0.65, 1.06)
		400 once daily	ND	15	1.15 (0.97, 1.36)	1.09 (0.94, 1.26)	0.99 (0.80, 1.23)
<b>Immunosuppressants</b>							
Cyclosporine <sup>h</sup>	600 single dose	400 single dose	ND	19	1.06 (0.94, 1.18)	0.98 (0.85, 1.14)	NA
		ND	100 single dose	12	0.92 (0.82, 1.02)	0.88 (0.78, 1.00)	NA
Tacrolimus <sup>h</sup>	5 single dose	400 single dose	ND	16	0.73 (0.59, 0.90)	1.09 (0.84, 1.40)	NA
<b>Opiate Agonists</b>							
R-Methadone <sup>h</sup>	30 to 130 daily	400 once daily	ND	14	0.99 (0.85, 1.16)	1.01 (0.85, 1.21)	0.94 (0.77, 1.14)
S-Methadone <sup>h</sup>					0.95 (0.79, 1.13)	0.95 (0.77, 1.17)	0.95 (0.74, 1.22)
<b>Statins</b>							
Atorvastatin	40 single dose	400 once daily	100 once daily	26	1.68 (1.49, 1.89)	1.54 (1.45, 1.64)	NA
Pravastatin <sup>h</sup>	40 single dose	ND	100 once	18	1.28	1.35	NA

Coadministered Drug	Dose of Coadministered Drug (mg)	Sofosbuvir dose (mg)	Velpatasvir Dose (mg)	N	Mean Ratio (90% CI) of Coadministered Drug PK With/Without Sofosbuvir, Velpatasvir or EPCLUSA No Effect=1.00		
					C <sub>max</sub>	AUC	C <sub>min</sub>
			daily		(1.08, 1.52)	(1.18, 1.54)	
Rosuvastatin <sup>h</sup>	10 single dose	ND	100 once daily	18	2.61 (2.32, 2.92)	2.69 (2.46, 2.94)	NA

NA = not available/not applicable; ND = not dosed

- All interaction studies conducted in healthy volunteers.
- Comparison based on exposures when administered as atazanavir/ritonavir + emtricitabine/tenofovir DF.
- Comparison based on exposures when administered as darunavir/ritonavir + emtricitabine/tenofovir DF.
- Administered as ATRIPLA (efavirenz, emtricitabine and tenofovir DF fixed-dose combination).
- Administered as GENVOYA (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide fixed-dose single tablet regimen).
- Administered as STRIBILD (elvitegravir, cobicistat, emtricitabine and tenofovir DF fixed-dose single tablet regimen).
- Administered as COMPLERA (emtricitabine, rilpivirine and tenofovir DF fixed-dose combination).
- These studies have not been performed with EPCLUSA; they were conducted with either sofosbuvir or velpatasvir administered as single agents.

### **Drug-Food Interactions**

No interactions between EPCLUSA and food have been identified.

### **Drug-Herb Interactions**

St. John's wort should not be used with EPCLUSA.

Coadministration of St. John's wort, a P-gp and a strong CYP inducer, may decrease sofosbuvir and velpatasvir plasma concentrations, which may result in loss of therapeutic effect. See **WARNINGS AND PRECAUTIONS, General, Use with P-gp Inducers and/or Moderate to Strong CYP Inducers.**

### **Drug-Laboratory Interactions**

Interactions of EPCLUSA with laboratory tests have not been established.

## **DOSAGE AND ADMINISTRATION**

### **Recommended Dose and Dosage Adjustment in Adults**

EPCLUSA is a single tablet regimen. No dosage adjustments are possible for EPCLUSA. The recommended dose of EPCLUSA is one tablet of 400 mg/100 mg sofosbuvir/velpatasvir, taken orally, once daily with or without food (see **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics, Effects of Food**).

The recommended dose and treatment duration for EPCLUSA is provided in Table 10.

**Table 10. Recommended Treatment Regimen for HCV Mono-infected and HCV/HIV-1 Co-infected Adult Patients<sup>a</sup> (All HCV Genotypes)**

<b>Patient Population</b>	<b>Recommended Dose and Duration of Treatment</b>
Patients without cirrhosis and patients with compensated cirrhosis	EPCLUSA one tablet daily for 12 weeks
Patients with decompensated cirrhosis <sup>b</sup>	EPCLUSA one tablet daily + ribavirin <sup>c</sup> for 12 weeks

- Refer to Tables 7-9 for dosing recommendations for concomitant HIV-1 antiviral agents and for observed drug exposure levels when co-administered with HIV antiviral agents (see **DRUG INTERACTIONS**).
- Limited data for genotypes 2, 4, 5 and 6 (see **WARNINGS AND PRECAUTIONS**, and **CLINICAL TRIALS**).
- When administered with EPCLUSA, the recommended dose of ribavirin is based on weight: 1000 mg per day for patients less than 75 kg and 1200 mg for those weighing at least 75 kg, divided and administered twice daily with food. For ribavirin dose modifications, refer to the Product Monograph containing ribavirin information.

### **Special Populations**

#### **Pediatrics (< 18 years of age)**

In pediatric patients  $\geq 12$  years of age and weighing  $\geq 30$  kg, the recommended dose of EPCLUSA is one 400/100 mg tablet taken orally, once daily with or without food for 12 weeks. No dose adjustments are possible for EPCLUSA.

EPCLUSA is not indicated for use in pediatric patients < 12 years of age or weighing < 30 kg.

#### **Geriatrics ( $\geq 65$ years of age)**

No dose adjustment is warranted for elderly patients (see **ACTION AND CLINICAL PHARMACOLOGY**).

#### **Hepatic Impairment**

No dose adjustment of EPCLUSA is required for adult patients with mild or moderate hepatic impairment (Child-Pugh A or B). Based on pharmacokinetic data, no dose adjustment of EPCLUSA is required for adult patients with Child-Pugh C hepatic impairment (see **ACTION AND CLINICAL PHARMACOLOGY**). However, safety and efficacy of EPCLUSA have not been established in adult patients with Child-Pugh C decompensated cirrhosis.

No dose adjustment of EPCLUSA is required for pediatric patients with mild hepatic impairment (Child-Pugh A). Safety and efficacy of EPCLUSA have not been established in pediatric patients with moderate or severe hepatic impairment (Child-Pugh B or C).

#### **Renal Impairment**

No dose adjustment of EPCLUSA is required for patients with any stage of renal impairment, including ESRD requiring dialysis (see **ADVERSE REACTIONS, ACTION AND CLINICAL PHARMACOLOGY** and **CLINICAL TRIALS**).

No safety data are available in patients with both decompensated cirrhosis (Child-Pugh B or C hepatic impairment) and severe renal impairment, including ESRD requiring dialysis. In addition, no safety data are available in pediatric patients with renal impairment.

When EPCLUSA is used in combination with ribavirin, refer also to the Product Monograph for ribavirin for patients with creatinine clearance < 50 mL/min.

### **Missed Dose**

If a patient misses a dose of EPCLUSA within 18 hours of the time it is usually taken, the patient should take EPCLUSA as soon as possible, and then take the next dose of EPCLUSA at the regularly scheduled time.

If a patient misses a dose of EPCLUSA and it is after 18 hours of the time it is usually taken, the patient should not take the missed dose, but resume the usual dosing schedule. A double dose of EPCLUSA must not be taken.

If a patient vomits less than 3 hours after taking a dose of EPCLUSA, the patient should take another dose of EPCLUSA. If a patient vomits more than 3 hours after taking a dose of EPCLUSA, the patient should take the next dose at the regularly scheduled time.

### **OVERDOSAGE**

For management of a suspected drug overdose, contact your regional Poison Control Centre.
---

Administration of activated charcoal may be used to aid in the removal of unabsorbed active substance. General supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient are recommended.

No specific antidote is available for overdose with EPCLUSA. If overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose with EPCLUSA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. Hemodialysis can efficiently remove the predominant circulating metabolite of sofosbuvir, GS-331007, with an extraction ratio of 53%. Hemodialysis is unlikely to result in significant removal of velpatasvir since velpatasvir is highly bound to plasma protein.

The highest documented doses of sofosbuvir and velpatasvir were a single dose of 1200 mg and a single dose of 500 mg, respectively. In these healthy volunteer studies, there were no untoward effects observed at these dose levels, and adverse events were similar in frequency and severity to those reported in the placebo groups. The effects of higher doses/exposures are not known.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Description**

EPCLUSA is a fixed-dose single tablet regimen of sofosbuvir and velpatasvir.

Sofosbuvir is a nucleotide analogue pan-genotypic NS5B polymerase inhibitor. Velpatasvir is a pan-genotypic HCV NS5A inhibitor.

### **Mechanism of Action**

#### **EPCLUSA**

Both sofosbuvir and velpatasvir exhibit high potency and specificity as individual agents against HCV as compounds that target the HCV NS5B and NS5A proteins, respectively. Both compounds display low cytotoxicity in a number of distinct cell lines and display no significant antiviral activity against other viruses tested. *In vitro* combination studies using both sofosbuvir and velpatasvir showed an additive effect as measured by *in vitro* cell based HCV replicon assays, with no antagonism detected. As individual components, both sofosbuvir and velpatasvir showed additive to synergistic activity with all other anti-HCV agents.

#### **Sofosbuvir**

Sofosbuvir is a pan-genotypic polymerase inhibitor of the HCV NS5B RNA-dependent RNA polymerase. Sofosbuvir is a monophosphorylated pyrimidine nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203).

#### **Velpatasvir**

Velpatasvir is a pan-genotypic HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA replication and the assembly of HCV virions. *In vitro* resistance selection and cross-resistance studies indicate velpatasvir targets NS5A as its mode of action.

### **Pharmacodynamics**

#### **Effect on Electrocardiogram**

The effects of administration of supratherapeutic doses of sofosbuvir (1200 mg) and velpatasvir (500 mg) (as individual drugs) demonstrated a lack of effect of sofosbuvir or velpatasvir on QTc interval.

## **Pharmacokinetics**

Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 1200 mg. Velpatasvir AUC increases in a greater than proportional manner from 5 to 50 mg and in a less than proportional manner from 50 to 450 mg, indicating velpatasvir absorption is solubility limited.

The pharmacokinetics of EPCLUSA are shown in Table 11.

**Table 11. Summary of Pharmacokinetics for Once-Daily Administration of EPCLUSA in Healthy Adult Subjects and HCV-Infected Patients**

PK Parameters	Healthy Subjects <sup>a</sup> EPCLUSA N = 331 Geometric Mean (Range)			HCV-Infected Patients <sup>b</sup> EPCLUSA N = 1428 Geometric Mean (Range)		
	SOF	GS-331007	VEL	SOF <sup>c</sup>	GS-331007	VEL <sup>d</sup>
	<b>AUC<sub>0-24</sub></b> <b>(ng·h/mL)</b>	1272 (543, 2348)	12040 (6983, 20488)	4556 (612, 12185)	1262 (337, 5333)	13967 (5217, 44182)
<b>C<sub>max</sub></b> <b>(ng/mL)</b>	550 (187, 1171)	817 (453, 1448)	421 (47, 1066)	566 (143, 1582)	868 (284, 2113)	259 (39, 977)
<b>C<sub>min</sub></b> <b>(ng/mL)</b>	ND	ND	65 (9, 243)	ND	ND	41 (5, 236)

ND = not determined; SOF = sofosbuvir; VEL = velpatasvir

a. Population PK analysis from Phase 1 studies.

b. Population PK analysis from Phase 2 and 3 studies.

c. N = 982; 446 patients did not have estimable PK parameters for SOF.

d. N = 1425; 3 patients did not have estimable PK parameters for VEL.

Based on population PK analyses, sofosbuvir and GS-331007 AUC<sub>0-24</sub> and C<sub>max</sub> were similar in healthy adult subjects and patients with HCV infection. Relative to healthy subjects (N=331), velpatasvir AUC<sub>0-24</sub> and C<sub>max</sub> were 37% lower and 41% lower, respectively, in HCV-infected patients. Age, race, BMI, HCV genotype or the presence or absence of cirrhosis had no clinically relevant effects on the exposure of sofosbuvir, GS-331007, or velpatasvir.

## **Absorption**

Following oral administration of EPCLUSA, sofosbuvir median peak plasma concentration was observed 0.5-1.0 hour post-dose. Median peak plasma concentration of GS-331007 was observed between 3.0 hours post-dose. Velpatasvir median peak concentrations were observed 3.0 hours post-dose.

## **Effects of Food**

Relative to fasting conditions, the administration (to healthy subjects) of a single dose of EPCLUSA with a moderate fat (~600 kcal, 30% fat) or high fat (~800 kcal, 50% fat) meal delayed the absorption of both sofosbuvir (median t<sub>max</sub> delayed from 0.5 hours to 2.0 hours) and velpatasvir (median t<sub>max</sub> delayed from 3.0 hours to 4.0 hours).

The extent of sofosbuvir absorption was significantly higher when administered with food (AUC increased 60% and 78% with a moderate fat or a high fat meal, respectively) and the  $C_{max}$  was unchanged. Food did not alter GS-331007 AUC but resulted in a 25% and 37% decrease in  $C_{max}$ , when EPCLUSA was administered with a moderate fat or a high fat meal, respectively.

The extent of velpatasvir absorption was increased more with a moderate fat meal (AUC increased 35% and  $C_{max}$  increased 31%) than with a high fat meal (AUC increased by 22% and no significant change in  $C_{max}$ ).

The response rates in Phase 3 trials were similar in HCV-infected patients who received EPCLUSA with food or without food. EPCLUSA can be administered without regard to food.

### **Distribution**

Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1  $\mu\text{g/mL}$  to 20  $\mu\text{g/mL}$ . Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [ $^{14}\text{C}$ ]-sofosbuvir in healthy subjects, the blood to plasma ratio of  $^{14}\text{C}$ -radioactivity was approximately 0.7.

Velpatasvir is > 99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09  $\mu\text{g/mL}$  to 1.8  $\mu\text{g/mL}$ . After a single 100 mg dose of [ $^{14}\text{C}$ ]-velpatasvir in healthy subjects, the blood to plasma ratio of  $^{14}\text{C}$ -radioactivity ranged between 0.52 and 0.67.

### **Metabolism**

Sofosbuvir is extensively metabolized in the liver to form the pharmacologically active nucleoside analog triphosphate, GS-461203. Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity *in vitro*. After a single 400 mg oral dose of [ $^{14}\text{C}$ ]-sofosbuvir, GS-331007 accounted for greater than 90% of total systemic exposure.

*In vitro*, slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was observed. Following a single dose of 100 mg [ $^{14}\text{C}$ ]-velpatasvir to healthy human male subjects, the majority (> 98%) of radioactivity in plasma was the parent drug. Unchanged velpatasvir is the major species present in feces.

### **Excretion**

Sofosbuvir is primarily eliminated in the urine as GS-331007. The median terminal half-lives of sofosbuvir and GS-331007 following administration of EPCLUSA were 0.5 and 25 hours, respectively.

Biliary excretion of parent drug was the major route of elimination for velpatasvir. The median terminal half-life of velpatasvir following administration of EPCLUSA was approximately 15 hours.

## **Special Populations and Conditions**

### **Pediatrics (< 18 years of age)**

Exposures of sofosbuvir, GS-331007 and velpatasvir in 102 pediatric patients  $\geq 12$  years of age who received EPCLUSA in Study GS-US-342-1143 were similar to those observed in adult patients following administration of EPCLUSA. Population pharmacokinetics-based simulations indicated exposures of sofosbuvir, GS-331007, and velpatasvir in pediatric patients weighing  $\geq 30$  kg receiving oral once daily doses of sofosbuvir/velpatasvir 400/100 mg were similar to those observed in adults.

The pharmacokinetics of sofosbuvir, GS-331007, and velpatasvir in pediatric patients < 12 years of age or weighing < 30 kg have not been established.

### **Geriatrics ( $\geq 65$ years of age)**

Based on population pharmacokinetic analyses, age did not have a clinically relevant effect on the exposure to sofosbuvir, GS-331007 or velpatasvir. Clinical studies of EPCLUSA included 156 patients aged 65 and over. The response rates observed for patients  $\geq 65$  years of age were similar to that of patients < 65 years of age, across treatment groups.

### **Gender**

No clinically relevant pharmacokinetic differences due to gender have been identified for sofosbuvir, GS-331007, or velpatasvir.

### **Race**

No clinically relevant pharmacokinetic differences due to race have been identified for sofosbuvir, GS-331007, or velpatasvir.

### **Hepatic Insufficiency**

Hepatic impairment studies were conducted with the individual drugs, sofosbuvir and velpatasvir.

The pharmacokinetics of sofosbuvir were studied following 7-day dosing of 400 mg sofosbuvir in HCV-infected patients with moderate and severe hepatic impairment (Child-Pugh B and C). Relative to subjects with normal hepatic function, the sofosbuvir  $AUC_{0-24}$  was 126% and 143% higher in moderate and severe hepatic impairment, while the GS-331007  $AUC_{0-24}$  was 18% and 9% higher, respectively. Mild hepatic impairment is not expected to meaningfully alter the pharmacokinetics of sofosbuvir and GS-331007. Population pharmacokinetics analysis in HCV-infected patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of sofosbuvir and GS-331007.

The pharmacokinetics of velpatasvir were studied with a single dose of 100 mg velpatasvir in HCV-negative subjects with moderate and severe hepatic impairment (Child-Pugh B and C). Velpatasvir plasma exposure ( $AUC_{inf}$ ) was similar in subjects with moderate hepatic impairment,



severe hepatic impairment, and control subjects with normal hepatic function. Population pharmacokinetics analysis in HCV-infected patients indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of velpatasvir.

### **Renal Insufficiency**

Renal impairment studies have been conducted with EPCLUSA or the individual drugs, sofosbuvir and velpatasvir.

The pharmacokinetics of sofosbuvir were studied in HCV negative subjects with mild (eGFR  $\geq 50$  and  $< 80$  mL/min/1.73m<sup>2</sup>), moderate (eGFR  $\geq 30$  and  $< 50$  mL/min/1.73m<sup>2</sup>), severe renal impairment (eGFR  $< 30$  mL/min/1.73m<sup>2</sup>) and subjects with ESRD requiring hemodialysis following a single 400 mg dose of sofosbuvir (N=6/group). Relative to subjects with normal renal function (eGFR  $> 80$  mL/min/1.73m<sup>2</sup>), the sofosbuvir AUC<sub>inf</sub> was 61%, 107% and 171% higher in mild, moderate and severe renal impairment, while the GS-331007 AUC<sub>inf</sub> was 55%, 88% and 451% higher, respectively. In subjects with ESRD, sofosbuvir AUC<sub>inf</sub> was 28% higher when sofosbuvir was dosed 1 hour before hemodialysis compared with 60% higher when dosed 1 hour after hemodialysis. The AUC<sub>inf</sub> of GS-331007 in subjects with ESRD administered sofosbuvir 1 hour before or 1 hour after hemodialysis was at least 10-fold and 20-fold higher, respectively, compared to normal subjects.

Hemodialysis can efficiently remove (53% extraction ratio) the predominant circulating metabolite GS-331007. Following a single 400 mg dose of sofosbuvir, a 4-hour hemodialysis session removed approximately 18% of administered dose.

Velpatasvir is primarily excreted in feces. Exposure of velpatasvir is not significantly impacted in the setting of severe renal impairment. The pharmacokinetics of velpatasvir were studied with a single dose of 100 mg velpatasvir in HCV negative subjects with severe renal impairment (eGFR  $< 30$  mL/min by Cockcroft-Gault). Velpatasvir AUC and C<sub>max</sub> were approximately 50% and 11% higher, respectively, in subjects with severe renal impairment compared to control subjects with normal renal function; these differences are not considered clinically relevant.

The pharmacokinetics of sofosbuvir, GS-331007, and velpatasvir were studied in HCV-infected patients with ESRD requiring dialysis treated with EPCLUSA for 12 weeks. Steady-state AUC<sub>tau</sub> of sofosbuvir, GS-331007, and velpatasvir were increased by 81%, 1719%, and 41%, respectively, compared to patients without renal impairment in the sofosbuvir/velpatasvir Phase 2/3 trials.

No dose adjustment of EPCLUSA is required for patients with any stage of renal impairment, including ESRD requiring dialysis.

No data are available regarding the safety of EPCLUSA in pediatric patients with renal impairment.

### **HCV/HIV-1 Co-infection**

The pharmacokinetics of sofosbuvir, GS-331007, and velpatasvir were similar in HCV/HIV-1 co-infected and HCV mono-infected adult patients.

### **STORAGE AND STABILITY**

Store below 30°C (86°F).

- Dispense only in original container.
- Do not use if seal over bottle opening is broken or missing.

### **SPECIAL HANDLING INSTRUCTIONS**

There are no special handling instructions.

### **DOSAGE FORMS, COMPOSITION AND PACKAGING**

EPCLUSA is a single tablet regimen containing sofosbuvir and velpatasvir for oral administration.

Each tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. The tablets include the following inactive ingredients: copovidone, croscarmellose sodium, magnesium stearate and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: iron oxide red, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

EPCLUSA is available as a pink-colored, diamond-shaped, film-coated tablet debossed with “GSP” on one side and “7916” on the other side of the tablet. Each bottle contains 28 tablets, a polyester coil and is closed with a child-resistant closure.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance


**Proper name:** sofosbuvir

**Chemical name:** (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate

**Molecular formula:** C<sub>22</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>9</sub>P

**Molecular mass:** 529.45

**Structural formula:**



**Physicochemical properties:**

**Appearance** Sofosbuvir is a white to off-white crystalline solid.

**Solubility** Sofosbuvir is slightly soluble in water.


**Proper name:** velpatasvir

**Chemical name:** Methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-5-methylpyrrolidin-2-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-yl}-1H-imidazol-2-yl)-4-(methoxymethyl)pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate

**Molecular formula:** C<sub>49</sub>H<sub>54</sub>N<sub>8</sub>O<sub>8</sub>

**Molecular mass:** 883.00

Structural formula:



Physicochemical  
properties:

Appearance	Velpatasvir is a white to tan or yellow solid.
Solubility	Velpatasvir is practically insoluble (< 0.1 mg/mL) above pH 5, slightly soluble (3.6 mg/mL) at pH 2.0, and soluble (> 36 mg/mL) at pH 1.2.

## CLINICAL TRIALS

The efficacy of EPCLUSA was evaluated in three Phase 3 trials in 1035 adult patients with genotype 1 to 6 chronic HCV infection without cirrhosis or with compensated cirrhosis. The efficacy of EPCLUSA was also evaluated in one Phase 3 trial in 267 adult patients with HCV infection with decompensated cirrhosis (ASTRAL-4). The demographics and baseline characteristics for the patients in studies ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 were balanced across the treatment groups for each study and are summarized in Table 13, Table 16, Table 19, and Table 22, respectively.

The efficacy of EPCLUSA in 106 HCV/HIV-1 co-infected adult patients, without cirrhosis or with compensated cirrhosis, was evaluated in an open-label Phase 3 trial (ASTRAL-5). All patients in the trial were treated with EPCLUSA for 12 weeks. The demographics and baseline characteristics for the patients in ASTRAL-5 are summarized in Table 25.

The efficacy of EPCLUSA in 59 patients with genotype 1, 2, 3, 4 and 6 chronic HCV infection without cirrhosis or with compensated cirrhosis, and with ESRD requiring dialysis was evaluated in one Phase 2 trial (Study GS-US-342-4062).

The ribavirin (RBV) dose was weight-based (1000 mg daily administered in two divided doses for adult patients < 75 kg and 1200 mg for those ≥ 75 kg) and administered in two divided doses when used in combination with sofosbuvir in the ASTRAL-2 and ASTRAL-3 trials or in combination with EPCLUSA in the ASTRAL-4 trial. RBV dose adjustments were performed according to the Product Monograph for RBV. Serum HCV RNA values were measured during the clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with a lower limit of quantification (LLOQ) of 15 IU per mL.

Sustained virologic response (SVR), defined as HCV RNA less than LLOQ at 12 weeks after the cessation of treatment, was the primary endpoint to determine the HCV cure rate.

The efficacy of EPCLUSA in HCV-infected pediatric patients  $\geq 12$  years of age was evaluated in 102 patients in an open-label Phase 2 trial (Study GS-US-342-1143, Cohort 1).

**Clinical Trials in Adult Patients Without Cirrhosis and Patients With Compensated Cirrhosis**

**Genotypes 1, 2, 4, 5, 6 HCV Infected Adults (ASTRAL-1)**

**Trial Design**

**Table 12. Summary of Trial Design in Genotypes 1, 2, 4, 5, 6 HCV Patients with or without Cirrhosis (ASTRAL-1)**

Trial Design	Dosage and Route of Administration	Treatment Regimen	Total Duration
Phase 3, randomized, double-blind, placebo-controlled, multicentre	EPCLUSA (400 mg/100 mg), QD, PO or Placebo, QD, PO	EPCLUSA	12 weeks
		Placebo	12 weeks

PO = orally; QD = once a day

Patients with genotype 1, 2, 4, or 6 HCV were randomized in a 5:1 ratio to treatment with EPCLUSA for 12 weeks or placebo for 12 weeks. Patients with genotype 5 HCV were enrolled to the EPCLUSA group. Randomization was stratified by HCV genotype (1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.

**Demographics and Other Baseline Characteristics**

**Table 13. Demographic and Other Baseline Characteristics of Genotypes 1, 2, 4, 5, 6 HCV Patients with or without Cirrhosis (ASTRAL-1)**

Characteristics	EPCLUSA 12 Weeks N = 624	Placebo 12 Weeks N = 116
<b>Age (years)</b>		
Mean (range)	54 (18-82)	53 (25-74)
<b>Gender, n (%)</b>		
Male	374 (60)	68 (59)
Female	250 (40)	48 (41)
<b>Race, n (%*)</b>		
White	493 (79)	90 (78)
Black	52 (8)	11 (9)
Asian	62 (10)	11 (9)
Other	14 (2)	4 (3)
Not disclosed	3 (< 1)	0
<b>BMI, n (%)</b>		
< 30 kg/m <sup>2</sup>	489 (78)	93 (80)
$\geq 30$ kg/m <sup>2</sup>	135 (22)	23 (20)
<b>Viral Load</b>		
HCV RNA Log <sub>10</sub> IU/mL, mean $\pm$ SD	6.3 $\pm$ 0.7	6.3 $\pm$ 0.6
< 800,000 copies/mL, n (%)	163 (26)	29 (25)
$\geq 800,000$ copies/mL, n (%)	461 (74)	87 (75)

Characteristics	EPCLUSA 12 Weeks N = 624	Placebo 12 Weeks N = 116
<b>HCV genotype, n (%*)</b>		
1	328 (53)	65 (56)
1a	210 (34)	46 (40)
1b	118 (19)	19 (16)
2	104 (17)	21 (18)
4	116 (19)	22 (19)
5	35 (6)	0
6	41 (7)	8 (7)
<b>IL28B, n (%*)</b>		
CC	186 (30)	36 (31)
Non-CC	433 (69)	79 (68)
Missing	5 (< 1)	1 (< 1)
<b>Cirrhosis, n (%*)</b>		
Yes (compensated)	121 (19)	21 (18)
No	501 (80)	95 (82)
Missing	2 (< 1)	0
<b>Treatment Status, n (%)</b>		
Treatment-naïve	423 (68)	83 (72)
Treatment experienced	201 (32)	33 (28)
<b>Prior HCV Treatment, n (%)</b>		
DAA + Peg-IFN + RBV	56/201 (28)	6/33 (18)
Peg-IFN+RBV	122/201 (61)	24/33 (73)
Other	23/201 (11)	3/33 (9)
<b>Prior HCV Response, n (%*)</b>		
Nonresponder	96/201 (48)	14/33 (42)
Relapse/Breakthrough	103/201 (51)	19/33 (58)
Not applicable	2/201 (< 1)	0/33

DAA = direct acting antiviral; Peg-IFN = pegylated interferon; RBV= ribavirin; SD = standard deviation

\*Total percentage may not add to 100% due to rounding.

## Study Results

The response rates for the EPCLUSA treatment group by HCV genotypes and for selected subgroups in the ASTRAL-1 trial are presented in Table 14. The EPCLUSA 12-week group met the primary endpoint of an SVR12 rate that was statistically superior relative to the prespecified performance goal of 85% ( $p < 0.001$ ). No patient in the EPCLUSA 12-week group had on-treatment virologic failure (ie, breakthrough, rebound or nonresponse). No patient in the placebo group achieved SVR12.

**Table 14. SVR12<sup>a</sup> and Treatment Outcomes in Genotypes 1, 2, 4, 5, 6 HCV Infected Patients with or without Cirrhosis and for Selected Subgroups (ASTRAL-1)**

	EPCLUSA 12 Weeks (N = 624)							
	Total (all GTs) (N=624) % (n/N)	GT-1			GT-2 (N=104) % (n/N)	GT-4 (N=116) % (n/N)	GT-5 (N=35) % (n/N)	GT-6 (N=41) % (n/N)
		GT-1a (N=210) % (n/N)	GT-1b (N=118) % (n/N)	Total (N=328) % (n/N)				
<b>Outcomes in Patients with SVR12</b>								
<b>SVR12</b>	99 (618/624)	98 (206/210)	99 (117/118)	98 (323/328)	100 (104/104)	100 (116/116)	97 (34/35)	100 (41/41)
95% CI <sup>b</sup>	(97.9, 99.6)	(95.2, 99.5)	(95.4, 100.0)	(96.5, 99.5)	(96.5, 100.0)	(96.9, 100.0)	(85.1, 99.9)	(91.4, 100.0)
<b>Cirrhosis</b>								
Yes (compensated)	99 (120/121)	100 (49/49)	96 (23/24)	99 (72/73)	100 (10/10)	100 (27/27)	100 (5/5)	100 (6/6)
No	99 (496/501)	98 (157/161)	100 (94/94)	98 (251/255)	100 (93/93)	100 (89/89)	97 (28/29)	100 (35/35)
Missing	100 (2/2)	0/0	0/0	0/0	100 (1/1)	0/0	100 (1/1)	0/0
<b>Prior HCV Treatment</b>								
Treatment-naïve	99 (418/423)	97 (128/132)	100 (86/86)	98 (214/218)	100 (79/79)	100 (64/64)	96 (23/24)	100 (38/38)
Treatment experienced	> 99 (200/201)	100 (78/78)	97 (31/32)	99 (109/110)	100 (25/25)	100 (52/52)	100 (11/11)	100 (3/3)
<b>Outcomes in Patients without SVR</b>								
Overall Virologic Failure	< 1 (2/624)	< 1 (1/210)	< 1 (1/118)	< 1 (2/328)	0/104	0/116	0/35	0/41
On-Treatment Virologic Failure	0/624	0/210	0/118	0/328	0/104	0/116	0/35	0/41
Relapse <sup>c</sup>	< 1 (2/623)	< 1 (1/209)	< 1 (1/118)	< 1 (2/327)	0/104	0/116	0/35	0/41
Other <sup>d</sup>	< 1 (4/624)	< 1 (3/210)	0/118	< 1 (3/328)	0/104	0/116	3 (1/35)	0/41

GT = genotype

- SVR12 = Sustained virologic response, defined as HCV RNA less than LLOQ (Lower Limit of Quantitation, 15 IU/mL) at 12 weeks after the cessation of treatment.
- The exact 95% CI for the proportion of within treatment group was based on the Clopper-Pearson method.
- The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
- Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

High SVR12 rates were achieved in all subgroups across all HCV genotypes. Among patients in the EPCLUSA 12-week group, the SVR12 rates in selected subgroups were as follows: with IL28B C/C allele (99.5%), non-CC (C/T or T/T) allele (98.8%); baseline HCV RNA < 800,000

IU/mL (98.8%), baseline HCV RNA  $\geq$  800,000 IU/mL (99.1%); baseline BMI  $<$  30 kg/m<sup>2</sup> (99.0%), baseline BMI  $\geq$  30 kg/m<sup>2</sup> (99.3%); sex (males [98.7%], females [99.6%]); and race (White [99.0%], Black [98.1%], Other [100.0%]). All patients previously treated with a DAA + Peg-IFN+RBV achieved SVR12 (56 of 56, 100%), which included 48, 6, and 2 patients with genotype 1, 4, and 5 HCV infection, respectively.

### **Genotype 2 HCV Infected Adults (ASTRAL-2)**

#### **Trial Design**

**Table 15. Summary of Trial Design in Genotype 2 HCV Patients with or without Cirrhosis (ASTRAL-2)**

<b>Trial Design</b>	<b>Dosage and Route of Administration</b>	<b>Treatment Regimen</b>	<b>Total Duration</b>
Phase 3, randomized, open label, multicentre	EPCLUSA (400 mg/100 mg), QD, PO	EPCLUSA	12 weeks
	or SOF 400 mg QD + RBV 1000 or 1200 mg/day, BID, PO	SOF+RBV	12 weeks

BID = twice a day; PO = orally; QD = once a day; RBV = ribavirin; SOF = sofosbuvir

Patients were randomized in a 1:1 ratio to treatment with EPCLUSA for 12 weeks or SOF+RBV for 12 weeks. Randomization was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment-naïve vs treatment experienced).

#### **Demographic and Baseline Characteristics**

**Table 16. Demographic and Other Baseline Characteristics of Genotype 2 HCV Patients with or without Cirrhosis (ASTRAL-2)**

<b>Characteristics</b>	<b>EPCLUSA 12 Weeks N = 134</b>	<b>SOF+RBV 12 Weeks N = 132</b>
<b>Age (years)</b>		
Mean (range)	57 (26-81)	57 (23-76)
<b>Gender, n (%)</b>		
Male	86 (64)	72 (55)
Female	48 (36)	60 (45)
<b>Race, n (%*)</b>		
White	124 (93)	111 (84)
Black	6 (4)	12 (9)
Asian	1 (< 1)	5 (4)
Other	1 (< 1)	3 (2)
Not disclosed	2 (1)	1 (< 1)
<b>BMI, n (%)</b>		
< 30 kg/m <sup>2</sup>	95 (71)	84 (64)
$\geq$ 30 kg/m <sup>2</sup>	39 (29)	48 (36)



Characteristics	EPCLUSA 12 Weeks N = 134	SOF+RBV 12 Weeks N = 132
<b>Viral Load</b>		
HCV RNA Log <sub>10</sub> IU/mL, mean ± SD	6.5 ± 0.8	6.4 ± 0.7
< 800,000 copies/mL, n (%)	23 (17)	31 (23)
≥ 800,000 copies/mL, n (%)	111 (83)	101 (77)
<b>HCV genotype, n (%)</b>		
2	134 (100)	132 (100)
2 (no confirmed subtype)	13 (10)	12 (9)
2a	2 (1)	4 (3)
2a/2c	16 (12)	12 (9)
2b	103 (77)	104 (79)
<b>IL28B, n (%)</b>		
CC	55 (41)	46 (35)
Non-CC	79 (59)	86 (65)
<b>Cirrhosis, n (%*)</b>		
Yes (compensated)	19 (14)	19 (14)
No	115 (86)	112 (85)
Missing	0	1 (< 1)
<b>Prior HCV Treatment Experience, n (%)</b>		
Treatment-naïve	115 (86)	112 (85)
Treatment experienced	19 (14)	20 (15)
<b>Prior HCV Treatment, n (%)</b>		
Peg-IFN+RBV	16/19 (84)	15/20 (75)
Other	3/19 (16)	5/20 (25)
<b>Prior HCV Response, n (%)</b>		
Nonresponder	3/19 (16)	3/20 (15)
Relapse/Breakthrough	16/19 (84)	17/20 (85)

Peg-IFN = pegylated interferon; RBV = ribavirin; SD = standard deviation; SOF = sofosbuvir

\*Total percentage may not add to 100% due to rounding.

## Study Results

The response rates for the treatment groups and for selected subgroups in the ASTRAL-2 trial are presented in Table 17. Treatment with EPCLUSA for 12 weeks demonstrated statistical superiority (p = 0.018) compared to treatment with SOF+RBV for 12 weeks (treatment difference +5.2%; 95% confidence interval: +0.2% to +10.3%).

**Table 17. SVR12<sup>a</sup> and Treatment Outcomes in Genotype 2 HCV Infected Patients with or without Cirrhosis and for Selected Subgroups (ASTRAL-2)**

	<b>EPCLUSA 12 Weeks N = 134 % (n/N)</b>	<b>SOF+RBV 12 Weeks N = 132 % (n/N)</b>
<b>Outcomes in Patients with SVR12</b>		
<b>SVR12</b>	99 (133/134)	94 (124/132)
95% CI <sup>b</sup>	(95.9, 100.0)	(88.4, 97.3)
<b>Genotype</b>		
2 (no confirmed subtype)	100 (13/13)	92 (11/12)
2a	100 (2/2)	100 (4/4)
2a/2c	100 (16/16)	92 (11/12)
2b	99 (102/103)	94 (98/104)
<b>Cirrhosis</b>		
Yes (compensated)	100 (19/19)	95 (18/19)
No	99 (114/115)	94 (105/112)
Missing	0/0	100 (1/1)
<b>Prior HCV Treatment</b>		
Treatment-naïve	99 (114/115)	96 (107/112)
Treatment experienced	100 (19/19)	85 (17/20)
Nonresponder	100 (3/3)	67 (2/3)
Relapse/Breakthrough	100 (16/16)	88 (15/17)
<b>Outcomes in Patients without SVR</b>		
Overall Virologic Failure	0/134	5 (6/132)
On-Treatment Virologic Failure	0/134	0/132
Relapse <sup>c</sup>	0/133	5 (6/132)
Other <sup>d</sup>	< 1 (1/134)	2 (2/132)

RBV = ribavirin; SOF = sofosbuvir

- SVR12 = Sustained virologic response, defined as HCV RNA less than LLOQ (Lower Limit of Quantitation, 15 IU/mL) at 12 weeks after the cessation of treatment.
- The exact 95% CI for the proportion of within treatment group was based on the Clopper-Pearson method.
- The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
- Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Among patients who received EPCLUSA for 12 weeks, the SVR12 rates in selected subgroups were as follows: with IL28B C/C allele (100.0%), non-CC (C/T or T/T) allele (98.7%); baseline HCV RNA < 800,000 IU/mL (100.0%), baseline HCV RNA ≥ 800,000 IU/mL (99.1%); baseline BMI of < 30 kg/m<sup>2</sup> (98.9%), baseline BMI ≥ 30 kg/m<sup>2</sup> (100.0%); sex (males [98.8%], females [100.0%]); and race (White [100.0%], Black [83.3%], Other [100.0%]).

### Genotype 3 HCV Infected Adults (ASTRAL-3)

#### Trial Design

**Table 18. Summary of Trial Design in Genotype 3 HCV Patients with or without Cirrhosis (ASTRAL-3)**

Trial Design	Dosage and Route of Administration	Treatment Regimen	Total Duration
Phase 3, randomized, open label, multicentre	EPCLUSA (400 mg/100 mg), QD, PO	EPCLUSA	12 weeks
	or SOF 400 mg QD, PO + RBV 1000 or 1200 mg/day, BID, PO	SOF+RBV	24 weeks

BID = twice a day; PO = orally; QD = once a day; RBV = ribavirin; SOF = sofosbuvir

Patients were randomized in a 1:1 ratio to treatment with EPCLUSA for 12 weeks or SOF+RBV for 24 weeks. Randomization was stratified by the presence or absence of cirrhosis and prior treatment experience (treatment-naïve vs treatment experienced).

#### Demographics and Other Baseline Characteristics

**Table 19. Demographic and Other Baseline Characteristics of Genotype 3 HCV Patients with or without Cirrhosis (ASTRAL-3)**

Characteristics	EPCLUSA 12 Weeks N = 277	SOF+RBV 24 Weeks N = 275
<b>Age (years)</b>		
Mean (range)	49 (21–76)	50 (19–74)
<b>Gender, n (%)</b>		
Male	170 (61)	174 (63)
Female	107 (39)	101 (37)
<b>Race, n (%*)</b>		
White	250 (90)	239 (87)
Black	3 (1)	1 (< 1)
Asian	23 (8)	29 (11)
Other	1 (< 1)	5 (2)
Not disclosed	0	1 (< 1)
<b>BMI, n (%)</b>		
< 30 kg/m <sup>2</sup>	226 (82)	214 (78)
≥ 30 kg/m <sup>2</sup>	51 (18)	61 (22)
<b>Viral Load</b>		
HCV RNA Log <sub>10</sub> IU/mL, mean ± SD	6.2 ± 0.7	6.3 ± 0.7
< 800,000 copies/mL, n (%)	86 (31)	81 (29)
≥ 800,000 copies/mL, n (%)	191 (69)	194 (71)
<b>HCV genotype, n (%*)</b>		
3	277 (100)	275 (100)
3a	265 (96)	250 (91)
3b	2 (< 1)	5 (2)
3h	0	2 (< 1)
3k	1 (< 1)	0

Characteristics	EPCLUSA 12 Weeks N = 277	SOF+RBV 24 Weeks N = 275
3 (no confirmed subtype)	9 (3)	18 (7)
<b>IL28B, n (%)</b>		
CC	105 (38)	111 (40)
Non-CC	172 (62)	164 (60)
<b>Cirrhosis, n (%)</b>		
Yes (compensated)	80 (29)	83 (30)
No	197 (71)	187 (68)
Missing	0	5 (2)
<b>Prior HCV Treatment Experience, n (%)</b>		
Treatment-naïve	206/277 (74)	204/275 (74)
Treatment experienced	71/277 (26)	71/275 (26)
<b>Prior HCV Treatment, n (%*)</b>		
DAA+Peg-IFN+RBV	1/71 (1)	0/71
Peg-IFN+RBV	64/71 (90)	65/71 (92)
Other	6/71 (8)	6/71 (8)
<b>Prior HCV Response, n (%)</b>		
Nonresponder	20/71 (28)	24/71 (34)
Relapse/Breakthrough	51/71 (72)	47/71 (66)

DAA = direct acting antiviral; Peg-IFN = pegylated interferon; RBV = ribavirin; SD = standard deviation; SOF = sofosbuvir

\*Total percentage may not add to 100% due to rounding.

## Study Results

The response rates for the treatment groups and for selected subgroups in study ASTRAL-3 are presented in Table 20. Treatment with EPCLUSA for 12 weeks demonstrated statistical superiority ( $p < 0.001$ ) compared to treatment with SOF+RBV for 24 weeks (treatment difference +14.8%; 95% confidence interval: +9.6% to +20.0%).

**Table 20. SVR12<sup>a</sup> and Treatment Outcomes in Genotype 3 HCV Infected Patients with or without Cirrhosis and for Selected Subgroups (ASTRAL-3)**

	EPCLUSA 12 Weeks N = 277 % (n/N)	SOF+RBV 24 Weeks N = 275 % (n/N)
<b>Outcomes in Patients with SVR12</b>		
<b>SVR12</b>	95 (264/277)	80 (221/275)
95% CI <sup>b</sup>	(92.1, 97.5)	(75.2, 84.9)
<b>Genotype</b>		
3a	95 (253/265)	80 (199/250)
3b	100 (2/2)	100 (5/5)
3h	0/0	100 (2/2)
3k	100 (1/1)	0/0
3 (no confirmed subtype)	89 (8/9)	83 (15/18)

	<b>EPCLUSA 12 Weeks N = 277 % (n/N)</b>	<b>SOF+RBV 24 Weeks N = 275 % (n/N)</b>
<b>Cirrhosis by Prior HCV Treatment</b>		
<u>Treatment-Naïve</u>		
With Cirrhosis (compensated)	93 (40/43)	73 (33/45)
Without Cirrhosis	98 (160/163)	90 (141/156)
Missing	0/0	67 (2/3)
<u>Treatment Experienced</u>		
With Cirrhosis (compensated)	89 (33/37)	58 (22/38)
Without Cirrhosis	91 (31/34)	71 (22/31)
Missing	0/0	50 (1/2)
<b>Response to Prior HCV Therapy</b>		
Nonresponder	85 (17/20)	58 (14/24)
Relapse/Breakthrough	92 (47/51)	66 (31/47)
<b>Prior HCV Therapy</b>		
DAA+PEG-IFN+RBV	100 (1/1)	0/0
PEG-IFN+RBV	89 (57/64)	63 (41/65)
Other	100 (6/6)	67 (4/6)
<b>Outcomes in Patients without SVR</b>		
Overall Virologic Failure	4 (11/277)	14 (39/275)
On-Treatment Virologic Failure	0/277	< 1 (1/275)
Relapse <sup>c</sup>	4 (11/276)	14 (38/272)
Other <sup>d</sup>	< 1 (2/277)	5 (15/275)

DAA = direct acting antiviral; Peg-IFN = pegylated interferon; RBV = ribavirin; SOF = sofosbuvir

- SVR12 = Sustained virologic response, defined as HCV RNA less than LLOQ (Lower Limit of Quantitation, 15 IU/mL) at 12 weeks after the cessation of treatment.
- The exact 95% CI for the proportion of within treatment group was based on the Clopper-Pearson method.
- The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
- Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Among patients who received EPCLUSA for 12 weeks, the SVR12 rates in selected subgroups were as follows: with IL28B C/C allele (94.3%), non-CC (C/T or T/T) allele (95.9%); baseline HCV RNA < 800,000 IU/mL (98.8%), baseline HCV RNA ≥ 800,000 IU/mL (93.7%); baseline BMI < 30 kg/m<sup>2</sup> (94.7%), baseline BMI ≥ 30 kg/m<sup>2</sup> (98.0%); sex (males [93.5%], females [98.1%]); and race (White [95.2%], Black [100.0%], Other [95.8%]). SVR12 rates for cirrhotic patients (91.3%) and treatment-experienced patients (90.1%) were higher in the EPCLUSA 12-week group compared with the SOF + RBV 24-week group.

The overall SVR12 (virologic cure) across the three trials (ASTRAL-1, ASTRAL-2, ASTRAL-3) was 98% (1015/1035).

## **Clinical Trial in Adult Patients with Decompensated Cirrhosis (ASTRAL-4)**

### **Trial Design**

**Table 21. Summary of Trial Design in HCV Patients with Decompensated Cirrhosis (ASTRAL-4)**

<b>Trial Design</b>	<b>Dosage and Route of Administration</b>	<b>Treatment Regimen</b>	<b>Total Duration</b>
Phase 3, randomized, open label, multicentre	EPCLUSA (400 mg/100 mg), QD, PO	EPCLUSA	12 weeks
	or EPCLUSA (400 mg/100 mg), QD, PO + RBV 1000 or 1200 mg/day, BID, PO	EPCLUSA + RBV	12 weeks
	or EPCLUSA (400 mg/100 mg), QD, PO	EPCLUSA	24 weeks

BID = twice a day; PO = orally; QD = once a day; RBV = ribavirin; SOF = sofosbuvir

Patients were randomized in a 1:1:1 ratio to treatment with EPCLUSA for 12 weeks, EPCLUSA + RBV for 12 weeks or EPCLUSA for 24 weeks. Randomization was stratified by HCV genotype (1, 2, 3, 4, 5, 6, and indeterminate). No patients with genotype 5 HCV infection were enrolled.

### **Demographics and Other Baseline Characteristics**

**Table 22. Demographic and Other Baseline Characteristics of HCV Patients with Decompensated Cirrhosis (ASTRAL-4)**

<b>Characteristics</b>	<b>EPCLUSA 12 Weeks N = 90</b>	<b>EPCLUSA + RBV 12 Weeks N = 87</b>	<b>EPCLUSA 24 Weeks N = 90</b>
<b>Age (years)</b>			
Mean (range)	58 (42-73)	58 (40-71)	58 (46-72)
<b>Gender, n (%)</b>			
Male	57 (63)	66 (76)	63 (70)
Female	33 (37)	21 (24)	27 (30)
<b>Race, n (%)</b>			
White	79 (88)	79 (91)	81 (90)
Black	6 (7)	5 (6)	6 (7)
Asian	3 (3)	0	2 (2)
Other	2 (2)	3 (3)	0
Not disclosed	0	0	1 (1)
<b>BMI, n (%)</b>			
< 30 kg/m <sup>2</sup>	48 (53)	54 (62)	52 (58)
≥ 30 kg/m <sup>2</sup>	42 (47)	33 (38)	38 (42)
<b>Viral Load</b>			
HCV RNA Log <sub>10</sub> IU/mL, mean ± SD	6.0 ± 0.5	5.8 ± 0.6	5.9 ± 0.6
< 800,000 copies/mL, n (%)	31 (34)	42 (48)	45 (50)
≥ 800,000 copies/mL, n (%)	59 (66)	45 (52)	45 (50)
<b>HCV genotype, n (%)*</b>			

Characteristics	EPCLUSA 12 Weeks N = 90	EPCLUSA + RBV 12 Weeks N = 87	EPCLUSA 24 Weeks N = 90
1	68 (76)	68 (78)	71 (79)
1a	50 (56)	54 (62)	55 (61)
1b	18 (20)	14 (16)	16 (18)
2	4 (4)	4 (5)	4 (4)
3	14 (16)	13 (15)	12 (13)
4	4 (4)	2 (2)	2 (2)
6	0	0	1 (1)
<b>IL28B, n (%)</b>			
CC	20 (22)	22 (25)	20 (22)
Non-CC	70 (78)	65 (75)	68 (76)
Missing	0	0	2 (2)
<b>Baseline CPT Score Category, n (%*)</b>			
CPT A [5-6]	3 (3)	6 (7)	7 (8)
CPT B [7-9]	86 (96)	77 (89)	77 (86)
CPT C [10-12]	1 (1)	4 (5)	6 (7)
<b>Baseline MELD Score Category, n (%*)</b>			
< 10	36 (40)	29 (33)	26 (29)
10-15	50 (56)	54 (62)	59 (66)
16-20	3 (3)	4 (5)	5 (6)
21-25	1 (1)	0	0
<b>Prior HCV Treatment Experience, n (%*)</b>			
Treatment-naïve	32 (36)	40 (46)	48 (53)
Treatment experienced	58 (64)	47 (54)	42 (47)
DAA+Peg-IFN+RBV	9/58 (16)	12/47 (26)	7/42 (17)
Peg-IFN+RBV	30/58 (52)	27/47 (57)	28/42 (67)
Other	18/58 (31)	8/47 (17)	7/42 (17)
Missing	1/58 (2)	0	0
<b>Prior HCV Response, n (%*)</b>			
Nonresponder	38/58 (66)	33/47 (70)	27/42 (64)
Relapse/Breakthrough	15/58 (26)	10/47 (21)	12/42 (29)
Not Applicable	4/58 (7)	4/47 (9)	3/42 (7)
Missing	1/58 (2)	0	0

CPT = Child-Pugh Turcotte; DAA = direct acting antiviral; MELD = model for end stage liver disease; Peg-IFN = pegylated interferon; RBV = ribavirin; SD = standard deviation

\*Total percentage may not add to 100% due to rounding.

## Study Results

Table 23 presents the SVR12 for the ASTRAL-4 trial by HCV genotype, the SVR12 for genotype 1 or 3 HCV infected patients stratified by prior HCV treatment, and virologic outcomes. All 3 treatment groups met their primary efficacy endpoints with SVR12 rates that were statistically superior compared with the assumed spontaneous rate of 1%. The p-value was < 0.001 for the comparison with the SVR12 for each treatment group.

**Table 23. SVR12 and Treatment Outcomes in Study ASTRAL-4 by HCV Genotype and Selected Subgroups**

	<b>EPCLUSA 12 Weeks (N = 90) % (n/N)</b>	<b>EPCLUSA + RBV 12 Weeks (N = 87) % (n/N)</b>	<b>EPCLUSA 24 Weeks (N = 90) % (n/N)</b>
<b>Outcomes in Patients with SVR12</b>			
<b>Overall SVR12</b> 95% CI <sup>a</sup>	83 (75/90) (74.0, 90.4)	94 (82/87) (87.1, 98.1)	86 (77/90) (76.6, 92.1)
Genotype 1	88 (60/68)	96 (65/68)	92 (65/71)
Genotype 1a	88 (44/50)	94 (51/54)	93 (51/55)
Genotype 1b	89 (16/18)	100 (14/14)	88 (14/16)
Genotype 3	50 (7/14)	85 (11/13)	50 (6/12)
Genotype 2, 4 and 6	100 (8/8) <sup>b</sup>	100 (6/6) <sup>c</sup>	86 (6/7) <sup>d</sup>
<b>Prior HCV Treatment<sup>e</sup></b>			
Treatment-Naïve			
Genotype 1	92 (22/24)	93 (25/27)	89 (33/37)
Genotype 3	50 (3/6)	80 (8/10)	60 (3/5)
Treatment-Experienced			
Genotype 1	86 (38/44)	98 (40/41)	94 (32/34)
Genotype 3	50 (4/8)	100 (3/3)	43 (3/7)
<b>Virologic Failure in Genotype 1 and 3 HCV-Infected Patients<sup>f</sup></b>			
Genotype 1 <sup>g</sup>	7 (5/68)	1 (1/68)	4 (3/71)
Genotype 1a	6 (3/50)	2 (1/54)	4 (2/55)
Genotype 1b	11 (2/18)	0 (0/14)	6 (1/16)
Genotype 3	43 (6/14)	15 (2 <sup>h</sup> /13)	42 (5 <sup>i</sup> /12)

RBV = ribavirin

a. The exact 95% CI for the proportion of within treatment group was based on the Clopper-Pearson method.

b. N=4 for genotype 2 and N=4 for genotype 4.

c. N=4 for genotype 2 and N=2 for genotype 4.

d. N=4 for genotype 2, N=2 for genotype 4 and N=1 for genotype 6.

e. Data for genotypes 2, 4, and 6 are not included.

f. Genotype 1 and 3 HCV patients who did not achieve SVR and did not have virologic failure are not included in this Table.

g. No patients with genotype 1 HCV had on-treatment virologic failure.

h. One patient had on-treatment virologic failure; PK data for this patient was consistent with non-adherence.



i. One patient had on-treatment virologic failure.

Note: There were no patients enrolled with genotype 5 infection.

The overall SVR12 (virologic cure) in ASTRAL-4 for the recommended treatment regimen was 94% (82/87). No patients with genotype 2, 4 or 6 HCV experienced virologic failure.

Among patients who received EPCLUSA + RBV for 12 weeks, the SVR12 rates in selected subgroups were as follows: with IL28B C/C allele (100.0%), non-CC (C/T or T/T) allele (92.3%); baseline HCV RNA < 800,000 IU/mL (95.2%), baseline HCV RNA ≥ 800,000 IU/mL (93.3%); baseline BMI < 30 kg/m<sup>2</sup> (92.6%), baseline BMI ≥ 30 kg/m<sup>2</sup> (97.0%); sex (males [92.4%], females [100.0%]); and race (White [93.7%], Black [100.0%], Other [100.0%]).

Changes in MELD and CPT score from baseline to post-treatment Week 12 (secondary endpoint) were analyzed for patients who achieved SVR12 and for whom data were available (N = 234) to assess the effect of SVR12 on hepatic function post-treatment. Of the 82 patients treated with EPCLUSA + RBV for 12 weeks who achieved SVR12, 81 had MELD and CPT assessments at baseline and post-treatment Week 12.

*Change in MELD score:* Among those who achieved SVR12 with 12 Weeks treatment with EPCLUSA + RBV, 51% (41/81) and 15% (12/81) had an improvement or no change in MELD score from baseline to post-treatment Week 12, respectively; of the 10 patients whose MELD score was ≥ 15 at baseline, 40% (4/10) had a MELD score < 15 at post-treatment Week 12. Improvement in MELD score was due to improvement (decreases) in bilirubin.

*Change in CPT:* Among those who achieved SVR12 with 12 Weeks treatment with EPCLUSA + RBV, 41% (33/81) and 49% (40/81) had an improvement or no change of CPT scores from baseline to post-treatment Week 12, respectively. Of the 72 patients who had CPT B cirrhosis at baseline, 11% (8/72) had CPT A cirrhosis at post-treatment Week 12. Improvement in CPT score was due to improvements in albumin (increases) and bilirubin (decreases).

Similar proportions of patients treated with EPCLUSA for 12 or 24 weeks had improvements in MELD and CPT scores compared with patients treated with EPCLUSA + RBV for 12 weeks.

### **Clinical Trial in Adult Patients with HCV/HIV-1 Co-infection (ASTRAL-5)**

#### **Trial Design**

**Table 24. Summary of Trial Design in Patients with HCV/HIV-1<sup>a</sup> Co-infection with or without Cirrhosis (ASTRAL-5)**

<b>Trial Design</b>	<b>Dosage and Route of Administration</b>	<b>Treatment Regimen</b>	<b>Total Duration</b>
Phase 3, open-label study, multicentre	EPCLUSA (400 mg/100 mg), QD, PO	EPCLUSA	12 weeks

PO = orally; QD = once a day

a. Patients were on a stable HIV-1 antiretroviral therapy that included emtricitabine/tenofovir disoproxil fumarate or abacavir/lamivudine administered with atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, raltegravir or elvitegravir/cobicistat.

## Demographics and Other Baseline Characteristics

**Table 25. Demographic and Other Baseline Characteristics of HCV/HIV-1 Co-infected Patients with or without Cirrhosis (ASTRAL-5)**

Characteristics	EPCLUSA 12 Weeks N = 106
<b>Age (years)</b>	
Mean (range)	54 (25-72)
<b>Gender, n (%)</b>	
Male	91 (86)
Female	15 (14)
<b>Race, n (%)</b>	
White	54 (51)
Black	48 (45)
Asian	3 (3)
Other	1 (1)
<b>BMI, n (%)</b>	
< 30 kg/m <sup>2</sup>	83 (78)
≥ 30 kg/m <sup>2</sup>	23 (22)
<b>Viral Load</b>	
HCV RNA Log <sub>10</sub> IU/mL, mean ± SD	6.3 ± 0.57
< 800,000 copies/mL, n (%)	28 (26)
≥ 800,000 copies/mL, n (%)	78 (74)
<b>HCV genotype, n (%*)</b>	
1	78 (74)
1a	66 (62)
1b	12 (11)
2	11 (10)
3	12 (11)
4	5 (5)
<b>IL28B, n (%)</b>	
CC	24 (23)
Non-CC	82 (77)
<b>Baseline CD4 T-cell Counts (cells/μL)</b>	
Mean (range)	598 (183-1513)
<b>Baseline CD4 T-cell Counts Category (cells/μL), n (%)</b>	
100 ≤ 200	2 (2)
201 ≤ 350	17 (16)
351 ≤ 500	27 (25)
> 500	60 (57)
<b>Cirrhosis, n (%)</b>	
Yes (compensated)	19 (18)
No	87 (82)
<b>HCV Treatment Status, n (%)</b>	
Treatment-naïve	75 (71)
Treatment experienced	31 (29)
<b>Prior HCV Treatment Experience, n (%)</b>	
DAA+Peg-IFN+RBV	1/31 (3)
Peg-IFN+RBV	21/31 (68)
Other	9/31 (29)

Characteristics	EPCLUSA 12 Weeks N = 106
<b>Prior HCV Response, n (%)*</b>	
Nonresponder	11/31 (35)
Relapse/Breakthrough	9/31 (29)
Other	11/31 (35)

DAA = direct acting antiviral; Peg-IFN = pegylated interferon; RBV= ribavirin; SD = standard deviation

\*Total percentage may not add to 100% due to rounding.

## Study Results

Table 26 presents the SVR12 for the ASTRAL-5 trial by HCV genotype and for selected subgroups.

**Table 26. SVR12<sup>a</sup> and Treatment Outcomes in HCV/HIV-1<sup>b</sup> Co-infected Patients with or without Cirrhosis and for Selected Subgroups (ASTRAL-5)**

	EPCLUSA 12 Weeks (N = 106)						
	Total (all GTs) (N=106) % (n/N)	GT-1			GT-2 (N=11) % (n/N)	GT-3 (N=12) % (n/N)	GT-4 (N=5) % (n/N)
		GT-1a (N=66) % (n/N)	GT-1b (N=12) % (n/N)	Total (N=78) % (n/N)			
<b>Outcomes in Patients with SVR12</b>							
<b>SVR12</b>	95 (101/106)	95 (63/66)	92 (11/12)	95 (74/78)	100 (11/11)	92 (11/12)	100 (5/5)
95% CI <sup>c</sup>	(89.3, 98.5)	(87.3, 99.1)	(61.5, 99.8)	(87.4, 98.6)	(71.5, 100.0)	(61.5, 99.8)	(47.8, 100.0)
<b>Cirrhosis</b>							
Yes (compensated)	100 (19/19)	100 (10/10)	100 (3/3)	100 (13/13)	100 (2/2)	100 (3/3)	100 (1/1)
No	94 (82/87)	95 (53/56)	89 (8/9)	94 (61/65)	100 (9/9)	89 (8/9)	100 (4/4)
<b>Prior HCV Treatment</b>							
Treatment-Naïve	95 (71/75)	96 (44/46)	90 (9/10)	95 (53/56)	100 (8/8)	89 (8/9)	100 (2/2)
Treatment-Experienced	97 (30/31)	95 (19/20)	100 (2/2)	95 (21/22)	100 (3/3)	100 (3/3)	100 (3/3)
<b>Outcomes in Patients without SVR</b>							
On-Treatment Virologic Failure	0/106	0/66	0/12	0/78	0/11	0/12	0/5
Relapse <sup>d</sup>	2 (2/103)	3 (2/65 <sup>e</sup> )	0/11	3 (2/76)	0/11	0/11	0/5
Other <sup>f</sup>	3 (3/106)	2 (1/66)	8 (1/12)	3 (2/78)	0/11	8 (1/12)	0/5

a. SVR12 = Sustained virologic response, defined as HCV RNA less than LLOQ (Lower Limit of Quantitation, 15 IU/mL) at 12 weeks after cessation of treatment.

b. Patients were on a stable HIV-1 antiretroviral therapy that included emtricitabine/tenofovir or abacavir/lamivudine administered with a ritonavir boosted protease-inhibitor (atazanavir, darunavir, or lopinavir),

rilpivirine, raltegravir or elvitegravir/cobicistat/emtricitabine/tenofovir DF.

c. The exact 95% CI for the proportion of within treatment group was based on the Clopper-Pearson method.

d. The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.

e. One GT-1a patient discontinued the study due to adverse event.

f. Other includes patients who did not achieve SVR and did not meet virologic failure criteria.

Among patients who received EPCLUSA for 12 weeks, the SVR12 rates in selected subgroups were as follows: with IL28B C/C allele (95.8%), non-CC (C/T or T/T) allele (95.1%); baseline HCV RNA < 800,000 IU/mL (96.4%), baseline HCV RNA ≥ 800,000 IU/mL (94.9%); baseline BMI < 30 kg/m<sup>2</sup> (96.4%), baseline BMI ≥ 30 kg/m<sup>2</sup> (91.3%); sex (males [96.7%], females [86.7%]); and race (White [96.3%], Black [93.8%], Other [100.0%]).

No patient had HIV-1 rebound during the study, and CD4+ counts were stable during treatment.

### **Clinical Trial in Patients with Renal Impairment**

Study GS-US-342-4062 was an open-label clinical trial that evaluated 12 weeks of treatment with EPCLUSA in 59 HCV-infected patients with ESRD requiring dialysis. The proportions of patients with genotype 1, 2, 3, 4, 6 or indeterminate HCV infection were 42%, 12%, 27%, 7%, 3%, and 9%, respectively. At baseline, 29% of patients had cirrhosis, 22% were treatment experienced, 32% had received a kidney transplant, 92% were on hemodialysis, and 8% were on peritoneal dialysis; mean duration on dialysis was 7.3 years (range: 0 to 40 years). The overall SVR rate was 95% (56/59); of the 3 patients that did not achieve SVR12, 1 had completed EPCLUSA treatment and relapsed and 2 did not meet virologic failure criteria.

### **Clinical Trial in Pediatric Patients**

#### **Trial Design and Study Demographics**

The efficacy of EPCLUSA once daily for 12 weeks in HCV-infected pediatric patients ≥ 12 years of age was evaluated in a Phase 2, open-label clinical trial (Study GS-US-342-1143, Cohort 1) in 102 pediatric patients with HCV infection. Pediatric patients with HIV-1 co-infection were excluded from the study. The demographic and baseline characteristics of this patient population are summarized in Table 27.

**Table 27. Demographic and Other Baseline Characteristics in Pediatric Patients (GS-US-342-1143, Cohort 1)**

Characteristics	EPCLUSA 12 Weeks N = 102
<b>Age (years)</b>	
Mean (range)	15 (12-17)
<b>Gender, n (%)</b>	
Male	50 (49)
Female	52 (51)

Characteristics	EPCLUSA 12 Weeks N = 102
<b>Race, n (%<sup>a</sup>)</b>	
White	74 (73)
Black	9 (9)
Asian	11 (11)
Other	8 (8)
<b>BMI (kg/m<sup>2</sup>)</b>	
Mean (range)	23 (13-49)
<b>Weight (kg)</b>	
Mean (range)	61 (22-147)
<b>Viral Load</b>	
HCV RNA Log <sub>10</sub> IU/mL, mean ± SD	6.1 ± 0.59
< 800,000 copies/mL, n (%)	43 (42)
≥ 800,000 copies/mL, n (%)	59 (58)
<b>HCV genotype, n (%<sup>a</sup>)</b>	
1	75 (74)
2	6 (6)
3	12 (12)
4	2 (2)
6	6 (6)
Missing <sup>b</sup>	1 (1)
<b>Cirrhosis, n (%)</b>	
Yes (compensated)	0 (0)
No	40 (39)
Not Determined	62 (61)
<b>HCV Treatment Status, n (%)</b>	
Treatment-naïve	80 (78)
Treatment-experienced	22 (22)

a. Total percentage may not add to 100% due to rounding.

b. The one patient with a missing HCV genotype at baseline was subsequently confirmed to have genotype 1b HCV infection.

## Study Results

Table 28 presents the response rates for pediatric patients by HCV genotype. The overall SVR rate was 95% (97/102; 95% confidence interval: 88.9% to 98.4%). One patient who discontinued treatment subsequently relapsed at Week 4; the other four patients who did not achieve SVR12 did not meet virologic failure criteria (eg, lost to follow-up).

**Table 28. Sustained Virologic Response (SVR12)<sup>a</sup> in Pediatric Patients (GS-US-342-1143, Cohort 1)**

	EPCLUSA 12 Weeks (N = 102)					
	Total (all GTs) (N=102) % (n/N)	GT-1 (N=76) % (n/N)	GT-2 (N=6) % (n/N)	GT-3 (N=12) % (n/N)	GT-4 (N=2) % (n/N)	GT-6 (N=6) % (n/N)
<b>Outcomes in Patients with SVR12</b>						
<b>SVR12</b>	95 (97/102)	93 (71/76)	100 (6/6)	100 (12/12)	100 (2/2)	100 (6/6)

a. SVR12 = Sustained virologic response, defined as HCV RNA less than LLOQ (Lower Limit of Quantitation, 15 IU/mL) at 12 weeks after cessation of treatment.

## MICROBIOLOGY

### Antiviral Activity in Cell Culture

The EC<sub>50</sub> values of sofosbuvir and velpatasvir against full-length or chimeric replicons encoding NS5B and NS5A sequences from the laboratory strains are presented in Table 29. The EC<sub>50</sub> values of sofosbuvir and velpatasvir against clinical isolates are presented in Table 30.

**Table 29. Activity of Sofosbuvir and Velpatasvir Against Full-Length or Chimeric Laboratory Replicons**

Replicon Genotype	Sofosbuvir EC <sub>50</sub> , nM <sup>a</sup>	Velpatasvir EC <sub>50</sub> , nM <sup>a</sup>
1a	40	0.014
1b	110	0.016
2a	50	0.005-0.016 <sup>c</sup>
2b	15 <sup>b</sup>	0.002-0.006 <sup>c</sup>
3a	50	0.004
4a	40	0.009
4d	NA	0.004
5a	15 <sup>b</sup>	0.021-0.054 <sup>d</sup>
6a	14 <sup>b</sup>	0.006-0.009
6e	NA	0.130 <sup>d</sup>

NA = not available

- Mean value from multiple experiments of same laboratory replicon.
- Stable chimeric 1b replicons carrying NS5B genes from genotype 2b, 5a or 6a were used for testing.
- Data from various strains of full-length NS5A replicon or chimeric NS5A replicons carrying full-length NS5A gene that contains L31 or M31 polymorphisms.
- Data from a chimeric NS5A replicon carrying NS5A amino acids 9-184.

**Table 30. Activity of Sofosbuvir and Velpatasvir Against Transient Replicons Containing NS5A or NS5B from Clinical Isolates**

Replicon Genotype	Replicons containing NS5B from clinical isolates		Replicons containing NS5A from clinical isolates	
	Number of clinical isolates	Median sofosbuvir EC <sub>50</sub> , nM (range)	Number of clinical isolates	Median velpatasvir EC <sub>50</sub> , nM (range)
1a	67	62 (29-128)	23	0.019 (0.011-0.078)
1b	29	102 (45-170)	34	0.012 (0.005-0.500)
2a	15	29 (14-81)	8	0.011 (0.006-0.364)
2b	NA	NA	16	0.002 (0.0003-0.007)
3a	106	81 (24-181)	38	0.005 (0.002-1.871)
4a	NA	NA	5	0.002 (0.001-0.004)
4d	NA	NA	10	0.007 (0.004-0.011)
4r	NA	NA	7	0.003 (0.002-0.006)
5a	NA	NA	42	0.005 (0.001-0.019)
6a	NA	NA	26	0.007 (0.0005-0.113)
6e	NA	NA	15	0.024 (0.005-0.433)

NA = not available

## **Resistance**

### **In Cell Culture**

HCV replicons with reduced susceptibility to sofosbuvir have been selected in cell culture for multiple genotypes including 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Reduced susceptibility to sofosbuvir was associated with the primary NS5B substitution S282T in all replicon genotypes examined. Site-directed mutagenesis of the S282T substitution in replicons of 8 genotypes conferred 2- to 18-fold reduced susceptibility to sofosbuvir and reduced the replication viral capacity by 89% to 99% compared to the corresponding wild-type. In biochemical assays, recombinant NS5B polymerase from genotypes 1b, 2a, 3a, and 4a expressing the S282T substitution showed reduced susceptibility to GS-461203 compared to respective wild-types.

*In vitro* selection of HCV replicons with reduced susceptibility to velpatasvir was performed in cell culture for multiple genotypes including 1a, 1b, 2a, 3a, 4a, 5a, and 6a. Variants were selected at NS5A resistance associated positions 24, 28, 30, 31, 32, 58, 92, and 93. The resistance associated variants (RAVs) selected in 2 or more genotypes were F28S, L31I/V, and Y93H. From site-directed mutagenesis studies, NS5A RAVs that showed a > 2.5-fold reduction in velpatasvir susceptibility are listed in Table 31 below. No individual substitutions tested in genotypes 2a, 4a, or 5a conferred a > 100-fold reduction in velpatasvir susceptibility (see **MICROBIOLOGY, Resistance, In Clinical Trials, Effect of Baseline HCV Resistance Associated Variants on Treatment Outcome**). Combinations of these variants often showed greater reductions in susceptibility to velpatasvir than single RAVs alone.

**Table 31. Phenotypic Change of Genotype 1-6 NS5A Substitutions to Velpatasvir**

Genotype	> 2.5-100-fold <sup>a</sup>	> 100-fold <sup>a</sup>
1a	M28A/T, Q30E/G/K, L31F/I/M/V, P32L, H58D, Y93C/L/S/T	M28G, A92K, Y93H/N/R/W
1b	Q24K, L31F/I, P58T, Y93H/N/T	A92K
2a	F28S, L31V, C92R, Y93H/N	None
2b	L28F, P58A, C92S, Y93F	C92T, Y93H/N
3a	A30H/K, L31F/M, P58G	Y93H
4a	L28T, Y93H/N/S	None
5a	L31I	None
6a	F28M/V, L31I/M, T58G/H, A92T, T93A/H/N/S	L31V, P32A/L/Q/R

a. Fold change was calculated as the ratio of mutant EC<sub>50</sub> to wild-type EC<sub>50</sub>.

## In Clinical Trials

### Studies in Adult Patients with Compensated Cirrhosis

In a pooled analysis of patients without cirrhosis or with compensated cirrhosis who received EPCLUSA for 12 weeks in Phase 3 trials (ASTRAL-1, ASTRAL-2, and ASTRAL-3), 12 patients (2 with genotype 1 and 10 with genotype 3) qualified for resistance analysis due to virologic failure. One additional virologic failure patient with genotype 3 HCV infection at baseline was reinfected with genotype 1a HCV at virologic failure and was excluded from the virological analysis. No patients with genotype 2, 4, 5, or 6 HCV infection experienced virologic failure.

Of the two genotype 1 virologic failure patients, one patient had virus with emergent NS5A RAV Y93N and the other patient had virus with emergent NS5A RAVs L31I/V and Y93H at virologic failure. Both patients had virus at baseline harboring NS5A RAVs. No NS5B nucleoside inhibitor (NI) RAVs were observed at failure in the two patients.

Of the ten genotype 3 virologic failure patients, Y93H was observed in all 10 patients at failure (6 had Y93H emerge post-treatment and 4 patients had Y93H at baseline and post-treatment). No NS5B NI RAVs were observed at failure in the ten patients.

### Studies in Adult Patients with Decompensated Cirrhosis

In the ASTRAL-4 trial in patients with decompensated cirrhosis who received EPCLUSA + RBV for 12 weeks, 3 patients (one with genotype 1 and two with genotype 3) qualified for resistance analysis due to virologic failure. No patients with genotype 2 or 4 HCV infection in the EPCLUSA + RBV 12-week group experienced virologic failure.



The one virologic failure patient with genotype 1 HCV had no NS5A or NS5B RAVs at failure.

Of the two genotype 3 virologic failure patients, one had NS5A RAV Y93H emerge at failure. Another patient had virus with Y93H at baseline and virologic failure and also developed low levels (< 5%) of NS5B NI RAVs N142T and E237G at failure. Pharmacokinetic data of this patient was consistent with non-adherence.

In the ASTRAL-4 trial, two patients treated with EPCLUSA for 12 or 24 weeks without ribavirin had emergent NS5B S282T at low levels (< 5%) along with L159F.

### Effect of Baseline HCV Resistance Associated Variants on Treatment Outcome

#### Adults

#### *Studies in Patients with Compensated Cirrhosis*

Analyses were conducted to explore the association between pre-existing baseline NS5A RAVs and treatment outcome for patients without cirrhosis or with compensated cirrhosis (ASTRAL-1, ASTRAL-2, and ASTRAL-3). Of the 1035 patients treated with EPCLUSA in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1023 patients were included in the analysis of NS5A RAVs; 7 patients were excluded as they neither achieved SVR12 nor had virologic failure and 5 additional patients were excluded as NS5A gene sequencing failed. In the pooled analysis of the Phase 3 trials, 380/1023 (37%) patients' virus had baseline NS5A RAVs. Genotype 2, 4, and 6 HCV infected patients had a higher prevalence of NS5A RAVs (70%, 63% and 52%, respectively) compared to genotype 1 (23%), genotype 3 (16%), and genotype 5 (18%) HCV infected patients.

SVR12 in patients with or without baseline NS5A RAVs in ASTRAL-1, ASTRAL-2, and ASTRAL-3 trials is shown in Table 32.

**Table 32. SVR12 in Patients with or without Baseline NS5A RAVs by HCV Genotype (ASTRAL-1, ASTRAL-2, ASTRAL-3)**

SVR12	EPCLUSA 12 Weeks			
	Genotype 1	Genotype 3	Genotype 2, 4, 5 or 6	Total
With any baseline NS5A RAVs	97% (73/75)	88% (38/43)	100% (262/262)	98% (373/380)
Without baseline NS5A RAVs	100% (251/251)	97% (225/231)	100% (161/161)	99% (637/643)

RAVs = resistance associated variants; RBV = ribavirin; SVR = sustained virologic response

Among the 75 genotype 1 patients who had baseline NS5A RAVs, SVR12 was 97% (67/69) and 100% (6/6) in patients with baseline NS5A RAVs that confer  $\leq$  100-fold and  $>$  100-fold reduced susceptibility to velpatasvir, respectively. Among the 43 genotype 3 patients who had baseline NS5A RAVs, SVR12 was 94% (15/16) and 85% (23/27) in patients with NS5A RAVs that confer  $\leq$  100-fold and  $>$  100-fold reduced susceptibility to velpatasvir, respectively. The four genotype 3 patients who had baseline NS5A RAVs conferring  $>$  100-fold reduced susceptibility to velpatasvir and failed to achieve SVR12 all had NS5A substitution Y93H at baseline. Twenty-one of 25 genotype 3 patients with baseline NS5A substitution Y93H achieved SVR12.

The NS5B NI RAV S282T was not detected in the baseline NS5B sequence of any patient in Phase 3 trials. SVR12 was achieved in all 77 patients who had baseline NS5B NI RAVs including N142T, L159F, E/N237G, C/M289L/I, L320F/I/V, V321A/I, and S282G+V321I.

### *Studies in Patients with Decompensated Cirrhosis*

Analyses were conducted to explore the association between pre-existing baseline NS5A RAVs and treatment outcome for patients with decompensated cirrhosis (ASTRAL-4). Of the 87 patients treated with EPCLUSA + RBV in the ASTRAL-4 study, 85 patients were included in the analysis of NS5A RAVs; 2 patients were excluded as they neither achieved SVR12 nor had virologic failure. Among the patients who received treatment with EPCLUSA + RBV for 12 weeks, 29% (25/85) of patients had baseline virus with NS5A RAVs [29% (19/66), 75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype 1, 2, 3 and 4 HCV, respectively].

SVR12 in patients with or without baseline NS5A RAVs in the EPCLUSA + RBV 12-week group of ASTRAL-4 trial is shown in Table 33.

**Table 33. SVR12 in Patients with or without Baseline NS5A RAVs by HCV Genotype (ASTRAL-4)**

	EPCLUSA + RBV 12 Weeks			
	Genotype 1	Genotype 3	Genotype 2 or 4	Total
With any baseline NS5A RAVs	100% (19/19)	50% (1/2)	100% (4/4)	96% (24/25)
Without baseline NS5A RAVs	98% (46/47)	91% (10/11)	100% (2/2)	98% (58/60)

RAVs = resistance associated variants; RBV = ribavirin

The single genotype 3 patient who had baseline NS5A RAVs and failed to achieve SVR12 had NS5A substitution Y93H at baseline and the pharmacokinetic data of this patient was consistent with non-adherence.

Three patients in the EPCLUSA + RBV 12-week group had baseline NS5B NI RAVs (N142T and L159F) and all three patients achieved SVR12.

### Pediatrics

In Study GS-US-342-1143, the presence of NS5A and NS5B RAVs did not impact treatment outcome; all pediatric patients 12 years to <18 years of age with baseline NS5A or NS5B NI RAVs (16.3% [16/98] and 5.2% [5/97], respectively) achieved SVR following 12 weeks treatment with EPCLUSA.

### Cross Resistance

Sofosbuvir retained activity against the NS5B substitutions L159F and L320F associated with resistance to other nucleoside inhibitors. *In vitro* data suggests that the majority of NS5A RAVs that confer resistance to ledipasvir and daclatasvir remained susceptible to velpatasvir. Velpatasvir was fully active against the sofosbuvir resistance-associated substitution S282T in NS5B while all velpatasvir resistance-associated substitutions in NS5A were fully susceptible to sofosbuvir. Both sofosbuvir and velpatasvir were fully active against substitutions associated with resistance to other classes of DAAs with different mechanisms of actions, such as NS5B non-nucleoside inhibitors and NS3 protease inhibitors. The efficacy of EPCLUSA has not been established in patients who have previously failed treatment with other regimens that include an NS5A inhibitor.

## **TOXICOLOGY**

### Repeat-Dose Toxicity

#### **Sofosbuvir**

Sofosbuvir or GS-9851, a 1:1 diastereomeric mixture of sofosbuvir and its stereoisomer, was evaluated in repeat-dose oral toxicity studies up to 13 weeks in mice, 26 weeks in rats, and 39 weeks in dogs. The primary sofosbuvir target organs identified were the gastrointestinal (GI) and hematopoietic (erythroid) systems. In a 7-day toxicity dog study with GS-9851, a dose of 1500 mg/kg/day resulted in (but were not limited to) increased mucus secretions in the stomach, glycogen depletion, and increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, with associated histopathologic liver findings and increased QT/QTc intervals in dogs. At the adverse dose, GS-331007 exposure levels in the dog study were at least 63-fold higher than HCV-infected patients treated once daily with EPCLUSA. In chronic toxicity studies in rats (26 weeks) and dogs (39 weeks), sofosbuvir effects included (but were not limited to) GI-related clinical signs (eg, soft feces and emesis) and a decrease (eg, approximately 10%) in mean red cell indices that were observed mainly in the high-dose group of dogs. One male dog was euthanized moribund with intestinal hemorrhage. The relationship to sofosbuvir was undetermined. In general, exposure levels in the chronic toxicity studies at the no observed adverse effect level were at least 5-fold (based on AUC of GS-331007) higher than HCV-infected patients treated once daily with EPCLUSA.

## **Velpatasvir**

Velpatasvir was well tolerated in studies for up to 4 weeks in the mouse, 26 weeks in the rat, and 39 weeks in the dog. No target organs were identified at the highest dose evaluated in each respective repeat dose toxicity study, corresponding to exposure margins of 74-, 5-, and 10-fold greater in mice, rats, and dogs, respectively, than those in HCV-infected patients treated once daily with EPCLUSA.

## **Genotoxicity and Carcinogenicity**

### **Sofosbuvir**

Sofosbuvir, when administered as the diastereomeric mixture GS-9851, was not genotoxic in a bacterial mutagenicity assay, in an *in vitro* chromosome aberration test using human peripheral blood lymphocytes and in an *in vivo* mouse micronucleus assay.

Sofosbuvir was not carcinogenic in the 2-year mouse and rat carcinogenicity studies at doses resulting in GS-331007 exposures up to 15-times in mice and 9-times in rats, higher than human exposure at 400 mg dose.

### **Velpatasvir**

Velpatasvir was not genotoxic in a battery of *in vitro* or *in vivo* assays, including bacterial mutagenicity, chromosome aberration using human peripheral blood lymphocytes and *in vivo* rat micronucleus assays.

Velpatasvir was not carcinogenic in the 26-week transgenic mouse and 2-year rat carcinogenicity studies at exposures up to 91- and 7-times, respectively, higher than human exposure.

## **Fertility**

### **Sofosbuvir**

Sofosbuvir had no effects on fertility when evaluated in rats at exposures (AUC) to the predominant circulating metabolite GS-331007 of at least 4-fold the exposure in humans at the recommended clinical dose.

Fertility was normal in the offspring of rats exposed daily from before birth (*in utero*) through lactation day 20 at daily GS-331007 exposures of approximately 6-fold higher than human exposures at the recommended clinical dose.

### **Velpatasvir**

Velpatasvir had no adverse effects on fertility in rats at AUC exposure 6-fold higher than the human exposure at the recommended clinical dose.

## REFERENCES

1. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. Discovery of a  $\beta$ -d-2'-deoxy-2'- $\alpha$ -fluoro-2'- $\beta$ -C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. *J Med Chem*. 2010;53(19):7202-18.
2. Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD, Smee DF, Frick DN, Heck JA, Wang P, Nagarathnam D, Ross BS, Sofia MJ, Otto MJ, Furman PA. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. *Antimicrob Agents Chemother*. 2010;54(8):3187-96.
3. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, *et al*. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. *N Engl J Med*. 2015;373(27):2608-17.
4. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, *et al*. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. *N Engl J Med*. 2015;373(27):2599-2607.
5. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, *et al*. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. *N Engl J Med*. 2015;373(27):2618-28.

## READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

### PATIENT MEDICATION INFORMATION

#### EPCLUSA® sofosbuvir and velpatasvir tablets

Read this carefully before you start taking **Epclusa**. Read it again every time you get a refill. This leaflet is a summary. It will not tell you everything about this drug. Talk to your doctor about your medical condition and treatment. Ask whether there is any new information about **Epclusa**.

#### Serious Warnings and Precautions

Hepatitis B activity (eg, inflamed liver) may increase when taking antiviral drugs like **Epclusa**, sometimes leading to liver failure and death. (See the “To help avoid side effects...” section, *Hepatitis B Reactivation*)

#### What is Epclusa used for?

- **Epclusa** treats chronic (lasting longer than 6 months) hepatitis C infection in adults and children 12 years of age and older and weighing 30 kg and more.
- **Epclusa** may be used with ribavirin, but not always. Read the ribavirin patient medication information if your doctor says you should also take ribavirin.

#### How does Epclusa work?

**Epclusa** contains two medicines, sofosbuvir and velpatasvir, that have been combined together into one tablet (pill). This type of treatment course (regimen) is also known as a single tablet regimen. It provides a complete treatment for hepatitis C. For most patients, **Epclusa** does not need to be taken with ribavirin.

- Sofosbuvir and velpatasvir block the virus from making more copies of itself in the body.
- **Epclusa** cures chronic hepatitis C in most patients. Cure means hepatitis C virus is cleared from your blood 3 months after finishing the medicine.

#### What are the ingredients in Epclusa?

Each tablet has the following medicines: sofosbuvir, velpatasvir.

Each tablet has the following ingredients that are not medicines: copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.

Each tablet is covered with the following ingredients that are not medicines: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.

#### Epclusa comes in the following dosage forms:

**Epclusa** comes in pink tablets. Each tablet contains 400 mg of sofosbuvir and 100 mg of

velpatasvir.

**Do not use Epclusa if:**

- You are allergic to velpatasvir, sofosbuvir or any of the other ingredients in this product. (Read also “**What are the ingredients in Epclusa?**” above.)
- You are taking **Epclusa** with ribavirin and you are pregnant or may become pregnant or if your partner(s) is (are) pregnant or may become pregnant. Ribavirin may cause birth defects or the death of your unborn baby.

**To help avoid side effects and make sure you take your medicine properly, talk to your doctor before you take Epclusa. Talk about any health problems you may have, including if you:**

- have liver problems other than hepatitis C infection.
  - have had a recent liver transplant.
  - have HIV.
  - are pregnant or plan to become pregnant (see “*Pregnancy and Birth Control*” below).
  - are breastfeeding or plan to breastfeed. Do NOT breastfeed while taking **Epclusa**.
  - are taking anything listed in the section “**The following may interact with Epclusa**”.
- 
- Your doctor may monitor your liver function during **Epclusa** treatment, under some conditions.

Your doctor may monitor your blood test results during **Epclusa** treatment if you have some conditions, for example, to check:

- how well your blood can clot if you take warfarin (Coumadin<sup>®</sup>) or other similar medicines called vitamin K antagonists, to thin the blood.
- blood sugar levels if you have diabetes.
- immunosuppressant drug levels if you receive immunosuppressive therapy.

***Hepatitis B Reactivation***

Taking antiviral drugs such as **Epclusa** may increase hepatitis B activity. This can lead to liver problems such as liver failure and death. Contact your doctor if:

- you have never been tested for hepatitis B.
- you know you have a current hepatitis B infection.
- you have had a previous hepatitis B infection.

Your healthcare provider may do blood tests:

- before hepatitis C treatment.
- to see the hepatitis B levels in your blood.
- and may order hepatitis B treatment.

### ***Pregnancy and Birth Control***

If you are pregnant or plan to become pregnant, ask your doctor for advice before taking this medicine. It is NOT known if **Epclusa** will harm your unborn baby.

**Epclusa** may be used with ribavirin. Ribavirin may cause birth defects and death of the unborn baby. Extreme care must be taken to avoid becoming pregnant.

- Females must have a negative pregnancy test before starting **Epclusa** and ribavirin, every month while on the medicine, and for 6 months after stopping them.
- You or your partner should not become pregnant while taking **Epclusa** with ribavirin and for 6 months after you have stopped taking them.
- You and your partner must use 2 kinds of birth control while taking **Epclusa** and ribavirin and for 6 months after you have stopped taking them.
- Talk to your doctor about the kind of birth control that you can use.
- If you or your partner becomes pregnant while taking **Epclusa** and ribavirin or within 6 months after you stop taking them, tell your doctor right away.

#### **Another warning you should know about:**

Because **Epclusa** already contains sofosbuvir, do not take **Epclusa** with any other medicines containing sofosbuvir (eg, **Sovaldi**<sup>®</sup>, **Harvoni**<sup>®</sup>, **Vosevi**<sup>®</sup>).

**Tell your doctor or pharmacist about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

#### **The following may interact with Epclusa:**

- amiodarone (Cordarone<sup>®</sup>), a drug used to treat irregular heartbeats (see “**What are possible side effects from using Epclusa?**”).
- atorvastatin (Lipitor<sup>®</sup>), a drug used to treat high cholesterol and to help prevent heart attacks and strokes.
- carbamazepine (Tegretol<sup>®</sup>), a drug used to treat seizures, nerve pain, and bipolar disorder.
- digoxin (Lanoxin<sup>®</sup>, Toloxin<sup>®</sup>), a drug used to treat congestive heart failure and a certain irregular heartbeat (atrial fibrillation).
- efavirenz (Sustiva<sup>®</sup>, **Atripla**<sup>®</sup>), a drug used to treat HIV.
- medicines for indigestion, heartburn, or ulcers. Examples are nizatidine (Axid<sup>®</sup>), famotidine (Pepcid AC<sup>®</sup>, Peptic Guard<sup>®</sup>, Ulcidine<sup>®</sup>), cimetidine (Tagamet<sup>®</sup>), ranitidine (Zantac<sup>®</sup>), esomeprazole (Nexium<sup>®</sup>), lansoprazole (Prevacid<sup>®</sup>), omeprazole (Losec<sup>®</sup>), rabeprazole (Aciphex<sup>®</sup>) and pantoprazole (Pantoloc<sup>®</sup>) or antacids (like Tums<sup>®</sup>, Rolaids<sup>®</sup> or Alka-Seltzer<sup>®</sup>) that have an ingredient to protect the stomach.
- oxcarbazepine (Trileptal<sup>®</sup>), a drug used to control seizures.
- phenobarbital, a drug used to treat anxiety and to control seizures.
- phenytoin (Dilantin<sup>®</sup>), a drug used to control seizures.
- rifabutin (Mycobutin<sup>®</sup>), a drug used to treat tuberculosis.
- rifampin (Rifadin<sup>®</sup>, Rifater<sup>®</sup>, Rofact<sup>®</sup>), a drug used to treat tuberculosis.
- rifapentine\*, a drug used to treat tuberculosis.



- rosvastatin (Crestor®), a drug used to treat high cholesterol and to help prevent heart attacks and strokes.
- St. John's wort (*Hypericum perforatum*), an herbal product used for anxiety or depression.
- tipranavir (Aptivus®) or tipranavir/ritonavir (Aptivus® and Norvir®), drugs used to treat HIV.
- tenofovir disoproxil fumarate (**Atripla**, **Complera**®, **Stribild**®, **Truvada**®, **Viread**®), to treat HIV.

\*Not sold in Canada.

### How to take Epclusa:

- Take this medicine with or without food.
- This medicine is taken for 12 weeks.
- If you are taking an antacid, you may need to take **Epclusa** at a different time than the antacid. Talk to your doctor or pharmacist.
- Do NOT stop taking **Epclusa** without first talking with your doctor.

### Usual dose:

Adults and children 12 years of age and older and weighing 30 kg and more:

- Take one tablet once each day.

### Overdose:

If you think you have taken too much **Epclusa**, contact your doctor or pharmacist, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

### Missed dose:

It is important to take **Epclusa** each day.

- **If you miss a dose of Epclusa** and you notice within 18 hours, take a tablet as soon as you can. Then take the next dose at your usual time.
- **If you miss a dose of Epclusa** and you notice after 18 hours, wait and take the next dose at your usual time. Do NOT take a double dose (two doses close together).

What to do if you vomit (throw up):

- If you vomit **less than 3 hours** after taking **Epclusa**, take another tablet.
- If you vomit **more than 3 hours** after taking **Epclusa**, wait. Do NOT take another tablet until you are scheduled to take the next tablet.

### What are possible side effects from using Epclusa?

If your side effect is not listed here, contact your doctor or pharmacist.

The most common side effects of **Epclusa** are: feeling tired and headache.

When sofosbuvir (one of the medicines in **Epclusa**) is used with other hepatitis C medicines (eg, daclatasvir [Daklinza®], simeprevir [Galexos®], or ledipasvir) and amiodarone (a heart drug),

side effects may be:

- slow heartbeat leading to a need for a pacemaker or death.

Contact your doctor immediately if you have symptoms of a slow heartbeat such as:

- fainting or near-fainting.
- dizziness or lightheadedness.
- not feeling well.
- feeling weak or very tired.
- shortness of breath.
- chest pains.
- confusion or memory problems.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your doctor.

### **Reporting side effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

#### **3 ways to report:**

- Online at MedEffect ([www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect));
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program  
Health Canada  
Postal Locator 1908C  
Ottawa, ON  
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect ([www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)).

*NOTE: Contact your doctor if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

### **Storage:**

- Store **Epclusa** below 30°C (86°F).
- Keep **Epclusa** in its original container.
- Do NOT use **Epclusa** if the seal over the bottle opening is broken or missing.
- Keep this medication where children cannot reach it or see it.

**If you want more information about Epclusa:**

- Talk to your doctor or pharmacist.
- Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<http://hc-sc.gc.ca/index-eng.php>); the manufacturer's website ([www.gilead.ca](http://www.gilead.ca)), or by calling 1-800-207-4267.

This leaflet was prepared by Gilead Sciences Canada, Inc.

Last Revised: November 5, 2020

**Gilead Sciences, Inc.**

Foster City, CA 94404  
USA

**Gilead Sciences Canada, Inc.**

Mississauga, ON L5N 2W3

ATRIPLA<sup>®</sup>, COMPLERA<sup>®</sup>, HARVONI<sup>®</sup>, EPCLUSA<sup>®</sup>, SOVALDI<sup>®</sup>, STRIBILD<sup>®</sup>, TRUVADA<sup>®</sup>, VIREAD<sup>®</sup>, and VOSEVI<sup>®</sup> are trademarks of Gilead Sciences, Inc. or its related companies.

All other marks referenced herein are the property of their respective owners.

© 2020 Gilead Sciences, Inc. All rights reserved.



e186388-GS-007